ORIGINAL ARTICLE

Association of obesity and other anthropometric characteristics with bladder cancer risk: a systematic review and metaanalysis of longitudinal cohort studies

Lazaros Tzelves¹, Dimitra Xenou², Andreas Skolarikos¹, Ioannis Varkarakis¹, Charalampos Deliveliotis¹, Evangelos Terpos², Kimon Stamatelopoulos², Theodoros N. Sergentanis^{2*}, Theodora Psaltopoulou^{2*}

¹2nd Department of Urology, Sismanoglio Hospital, Medical School, National and Kapodistrian University of Athens, Sismanogliou 37 street, Athens, Greece. ²Department of Clinical Therapeutics, ''Alexandra'' Hospital, Medical School, National and Kapodistrian University of Athens, 80 Vas. Sofias Ave, Athens, Greece.

*These authors contributed equally to this work.

Summary

Purpose: The purpose of this systematic review and metaanalysis was to evaluate the potential associations between anthropometric characteristics and bladder cancer risk, synthesizing longitudinal cohort studies.

Methods: Literature search across MEDLINE, EMBASE, Scopus, Google Scholar and Cochrane Central was performed up to December 31, 2019 and data abstraction was performed independently by two authors. Random-effects (DerSimonian-Laird) models were used to estimate pooled relative risks (RR) and 95% confidence intervals (95%CI); subgroup analyses were performed in geographical region, mean age, publication year, length of follow-up, sample size, method of body mass index (BMI) estimation and adjust*ment for smoking.*

Results: 27 studies were included (88 593 bladder cancer cases in a total cohort of 49 647 098 subjects). Increased

bladder cancer risk was noted in overweight men (pooled RR=1.12, 95%CI: 1.04-1.21) but not in overweight women. Both obese men (pooled RR=1.14, 95%CI: 1.06-1.22) and women (pooled RR=1.19, 95%CI: 1.02-1.38) showed increased risk. Interestingly, height increase per 5 cm did not seem to affect risk of bladder cancer in men (pooled RR=1.03, 95%CI: 0.99- 1.06) and women (pooled RR=1.02, 95%CI: 0.97-1.06). Larger waist circumference was associated with bladder cancer risk in men (pooled RR=1.18, 95%CI: 1.09-1.26) but not women.

Conclusion: Bladder cancer risk seems to be related with obesity overall and central obesity in men. In contrast to other cancer types, height does not seem to affect risk, but more studies are needed to extract safe conclusions.

Key words: BMI, cohort studies, meta-analysis, obesity, urinary bladder cancer, waist circumference

Introduction

cancer worldwide, and sixth most common in developed countries [1,2]. The natural course of this disease is considered a major healthcare economic burden in Western countries [3] with the majority of costs being directed to surveillance procedures

Bladder cancer is the ninth most common and management of complications [4]. Most cases represent non-muscle invasive disease (70-75%), while the remaining 25% are muscle-invasive.

> Many studies have been conducted to establish a risk factor profile for bladder cancer. Age is considered the single most important non-modifi-

Corresponding author: Dr. Lazaros Tzelves. 2nd Department of Urology, Sismanoglio Hospital, Medical School, National and Kapodistrian University of Athens, Sismanogliou 37 street, Athens, Greece. Tel: +30 2132058253; Email: lazarostzelves@gmail.com

Received: 22/12/2020; Accepted: 17/01/2021



able risk factor, with most patients diagnosed at a median age of 70 years [5]. Occupational exposure is associated with slightly increased incidence of the disease in miners, rubber and leather industry workers, bus drivers, mechanics, firefighters and hair dressers especially when working more than 10 years [6-8]. Tobacco smoking has been clearly linked to bladder cancer occurrence showing a doseresponse relationship, with cigarette use leading to a 3 to 5 fold increase in risk, depending on intensity and duration of smoking [9]. Other environmental factors and dietary habits, such as high concentrations of arsenic in tap water [10] radiation exposure [11] diabetes mellitus [12] high intake of salt and red meat [13] and Schistosoma hematobium infection, seem to increase likelihood of bladder cancer.

Owing to the modern lifestyle and unhealthy eating habits, obesity consists a "pandemic" with prevalence ranging between 30-60% worldwide for total overweight and obese people [14]. Overweight and obese subjects are at greater risk for certain types of neoplasms [15]. Kanabrocki et al were the first who linked obesity to bladder carcinoma, back in 1965 [16] and since then a number of studieshave tried to quantify the risk, with conflicting results. At the level of meta-analyses, in 2011 Qin et al [17] synthesized 11 cohort studies and detected a strong relationship between bladder cancer and obesity, which increased the risk by 10%; in 2015, Sun et al [18] confirmed this association. In 2017, Zhao et al [19] performed a meta-analysis of 14prospective cohort studies and concluded that a nonlinear association between body mass index (BMI) and bladder cancer exists.

Regarding other anthropometric characteristics, height has been associated with various cancers [20]; however, no meta-analysis has evaluated the association between height and bladder cancer risk. In addition, central obesity, reflected upon waist circumference has not been studied with respect to bladder cancer at the meta-analytical level.

The purpose of this systematic review and meta-analysis was to synthesize the existing evidence regarding the association between overweight, obesity, and other anthropometric characteristics,namely height and waist circumference, with bladder cancer risk in adults, based on longitudinal cohort studies.

Methods

Search algorithm, inclusion and exclusion criteria

This systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines [21]. Two researchers (L.T., D.X.) performed an electronic review of the literature independently, to identify published articles in English language across several databases (MEDLINE, Cochrane Database of Systematic Reviews, EMBASE, Scopus, Google Scholar) until December 31, 2019. The algorithm used for search was : ("Urothelium" OR "urothelial" OR "UCC" OR "transitional cell" OR "TCC" OR "bladder") AND ("neoplasms" OR "neoplasm" OR "cancer" OR "cancers" OR "carcinoma" OR "carcinomas" OR "tumor" OR "tumour" OR "tumors" OR "tumours" OR "neoplasia") AND ("prospective" OR "prospectively" OR "follow-up" OR "followed up" OR "cohort" OR "cohorts" OR "longitudinal") AND ("overweighted" OR "overweight" OR "BMI" OR "obesity" OR "body mass index" OR "adiposity" OR "body size" OR "obese" OR "body weight" OR "height" OR "waist"). Studies were reviewed by title and/or abstract and the most relevant were full-text reviewed. Reference lists of included articles and previous reviews/meta-analyses were searched for relevant studies ("snowball procedure"). Only cohort studies focusing on the association of anthropometric characteristics with risk of bladder cancer in men or women were considered eligible, while comments, expert opinions, casecontrol and caseseries studies were excluded. Eligible articles examined the association between various anthropometric characteristics (BMI, height, waist to hip ratio, waist circumference) with incidence of urinary bladder carcinoma.

When studies' populations overlapped, only the study with the larger cohort and longer follow-up period was included. Disagreements were resolved upon consensus with a third, independent reviewer (T.N.S.).

Data abstraction

Two authors (L.T., D.X.) performed data abstraction independently based on a standard spreadsheet recording study information (year of publication, journal, first author, baseline characteristics of cohorts, sample size, age mean/ range, cases of bladder cancer, method of measurement of anthropometric characteristics, followup length, period and region where study was conducted and adjusting factors, as well as statistical measures used, namely relative risks (RR), hazard ratios (HR) and person-years). When more than one estimates per outcome was reported, the maximally adjusted effect estimate was extracted along with the relevant confidence interval (CI). In case of disagreements, consensus was reached after consensus with a third author (T.N.S.).

Statistical analysis: meta-analysis

In this study the term "study arms" refers to separate BMI categories, defined as overweight for BMI=25-30 kg/m² and obese for BMI>30 kg/m². Comparisons were made between overweight/obese with normal weight, separately for men and women. For the calculation of open-ended categories $\geq a$, the lower bound was multiplied by 1.2, as indicated by Berlin et al [22]. Subgroup analysis was performed by different geographical regions incorporating one study from Israel within Europe group, mean age (\geq 50 and <50 years), publication year (from 2011 onwards and before 2011), length of follow-up (\geq 10 and<10 years), sample size (\geq 300 000 and <300 000), method of

BMI estimation (measured; self-reported) and adjustment for smoking. Calculation of pooled effect estimate was performed using random effects model (DerSimonian-Laird, with the estimate of heterogeneity taken from the Mantel-Haenszel model). Assessment of heterogeneity between studies was done with Q-statistic (Cochran) and I² [23]. A synthesis of studies providing incremental estimations for height was performed; the effect estimates were transformed to reflect a 5 cm increase in height. Statistical analysis was performed with STATA/ SE version 13 (Stata Corp, College Station, TX, USA).

Assessment of risk of bias

Newcastle-Ottawa scale for observational cohort studies [24] a nine-item tool of study quality assessment, was used in order to evaluate each study regarding the selection of participants, comparability of groups and outcome assessment. Follow-up cut-off value in order to give a study a star was set a priori at 10 years, which is a long enough period to observe neoplasms incidence. Adequacy of follow-up in terms of loss-to-follow-up was set at 85% response rate. Two authors assessed the risk of bias independently (L.T., D.X.) and disagreements were resolved by consensus with a third reviewer (T.N.S.).

We evaluated existence of publication bias via Egger's statistical test and visual inspection of funnel plots.

Results

Overall, 801 abstracts and titles were identified and screened through literature search. 771 of them were excluded by title screening due to irrelevance, while the remaining 30 studies were assessed after full-text review. Six studies were excluded due to reporting reasons and one due to language restriction (Chinese language). In addition, six more studies were eligible for inclusion through reference screening from the included studies ("snowball procedure"). The male arm in the study by Jee et al [25] was excluded due to overlap with the study by Oh et al [26], which spanned a longer time period (1992-2001 vs 1992-1995). The male arm of Lee et al study [27] for waist circumference was also excluded due to overlap with the study by Choi JB et al [28]. Finally, after excluding two more studies due to overlapping populations, 27 studies were eligible for inclusion (88 593 bladder cancer cases in a total cohort of 49 647 098 subjects) [25-51]. The process of study selection is depicted graphically in Supplemental Figure 1.

Overweight/obesity and risk of urinary bladder cancer: overall analysis and subgroup analyses by geographical region

Results of meta-analysis regarding association between overweight, obesity and risk of bladder cancer is shown in Table 1 for overweight and obese men and women. Pooled analysis of 17 study arms examining the risk of bladder cancer in overweight men resulted in a significant association (pooled RR=1.12, 95% CI: 1.04-1.21, Figure 1A); a similar finding was noted in the synthesis of19 study arms in obese men (pooled RR=1.14, 95% CI: 1.06-1.22, Figure 1B). In overweight women pooled analysis of 16 study arms did not show an increased risk (pooled RR=1.06, 95% CI: 0.96-1.17, Figure 1C);in contrast, the synthesis of 15 arms regarding obese women resulted in a significantly increased risk (pooled RR=1.19, 95% CI: 1.02-1.38, Figure 1D).

Table 1. Results of the meta-analyses examining the association between BMI and risk of bladder cancer

		Overweight	t		Obese	
	n*	RR (95%CI)	Heterogeneity I², p	n*	RR (95%CI)	Heterogeneity I², p
Men						
Overall	17	1.12 (1.04, 1.21)	64.8%, <0.001	19	1.14 (1.06, 1.22)	40.9%, 0.033
Geographical region						
Australia	1	1.51 (1.15, 1.98)	%	1	1.70 (1.23, 1.34)	%
East Asia	3	1.19 (1.15, 1.23)	0%, 0.869	2	1.17 (1.05, 1.29)	0%, 0.383
Europe	9	1.06 (0.95, 1.18)	60.8%, 0.009	10	1.11 (0.97, 1.26)	41.6%, 0.080
US/Canada	4	1.19 (1.07, 1.32)	0%, 0.955	6	1.12 (1.01, 1.24)	34.5%, 0.177
Women						
Overall	16	1.06 (0.96, 1.17)	18.0%, 0.248	15	1.19 (1.02, 1.38)	40.6%, 0.051
Geographical region						
Australia	1	1.30 (0.92, 1.83)	%	1	2.03 (1.42, 2.90)	%
East Asia	1	1.10 (0.75, 1.62)	%	1	0.74 (0.27, 2.04)	%
Europe	7	1.08 (0.91, 1.29)	41.0%, 0.118	7	1.08 (0.94, 1.23)	4.8%, 0.390
US/Canada	7	0.98 (0.84, 1.15)	0%, 0.473	6	1.23 (1.00, 1.51)	6.9%, 0.373

*number of study arms

A 5

В

Study ID	RR (95% CI)	% Weigh
Australia		
_aaksonen males BMI 25.0–29.9 (2019)	1.51 (1.15, 1.98)	4.62
Subtotal (I–squared = .%, p = .)	1.51 (1.15, 1.98)	4.62
ast Asia		
thoi JB males BMI 25.0–29.9 (2019)	1.19 (1.15, 1.23)	12.33
Dh males BMI 25.0–26.9 (2005)	1.12 (0.89, 1.41)	5.64
Dh males BMI 27.0–29.9 (2005)	1.16 (0.83, 1.62)	3.53
Subtotal (I–squared = 0.0%, p = 0.869)	1.19 (1.15, 1.23)	21.50
urope		
laggstrom males BMI 25.4 (2010)	1.06 (0.89, 1.27)	7.20
laggstrom males BMI 27.1 (2010)	0.97 (0.81, 1.17)	6.98
arsson males BMI 25.0–29.9 (2007)	0.98 (0.80, 1.21)	6.24
Rapp males BMI 25.0–29.9 (2005)	0.81 (0.59, 1.11)	3.78
Roswall males BMI 24.52–26.45 (2014)	1.20 (1.01, 1.43)	7.40
toswall males BMI 26.46–28.96 (2014)	- 1.11 (0.93, 1.33)	7.22
amanic males BMI 25.0–29.9 (2006)	0.94 (0.86, 1.03)	10.62
ong males BMI 25.0–27.4 (2014)	1.48 (0.95, 2.31)	2.22
iong males BMI 27.5–29.9 (2014)	♦ 1.95 (1.24, 3.08)	2.14
ubtotal (I–squared = 60.8%, p = 0.009)	1.06 (0.95, 1.18)	53.80
1		
JS/Canada		
Andreotti males BMI 25.0–29.9 (2010)	1.16 (0.75, 1.80)	2.27
lolick males BMI 25.0–26.9 (2007)	1.14 (0.86, 1.51)	4.42
lolick males BMI 27.0–29.9 (2007)	1.12 (0.83, 1.51)	4.07
Koebnick males BMI 25.0–29.9 (2008)	- 1.21 (1.07, 1.37)	9.31
Subtotal (I–squared = 0.0%, p = 0.955)	1.19 (1.07, 1.32)	20.08
Overall (I–squared = 64.8%, p = 0.000)	1.12 (1.04, 1.21)	100.0
NOTE: Weights are from random effects analysis		
.325 1	3.08	
	3.08	
Study	3.08 RR (95% CI)	% Weigł
Study D		2.2
itudy D Australia	RR (95% CI)	Weigh
itudy D Australia aaksonen males BMI >=30.0 (2019)	RR (95% CI)	Weigh
itudy D	RR (95% CI)	Weigh
Study D Australia .aaksonen males BMI >=30.0 (2019) Subtotal (I–squared = .%, p = .)	RR (95% CI)	Weigh
itudy D Australia .aaksonen males BMI >=30.0 (2019) Jubtotal (I–squared = .%, p = .)	RR (95% CI) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34)	Weigl 3.88 3.88
tudy D ustralia aaksonen males BMI >=30.0 (2019) ubtotal (I–squared = .%, p = .) ast Asia hoi JB males BMI >=30.0 (2019)	RR (95% CI)	Weigl 3.88 3.88 13.15
tudy D uustralia aaksonen males BMI >=30.0 (2019) uubtotal (Isquared = .%, p = .) ast Asia ihoi JB males BMI >=30.0 (2019) th males BMI >=30.0 (2005)	RR (95% CI) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34)	Weigl 3.88 3.88 13.15 0.38
tudy D uustralia aaksonen males BMI >=30.0 (2019) uubtotal (Isquared = .%, p = .) ast Asia ihoi JB males BMI >=30.0 (2019) th males BMI >=30.0 (2005)	RR (95% CI)	Weigl 3.88 3.88 13.15 0.38
itudy D Australia aaksonen males BMI >=30.0 (2019)	RR (95% CI)	Weigl 3.88 3.88 13.15
itudy D Australia .aaksonen males BMI >=30.0 (2019) iubtotal (I-squared = .%, p = .) :ast Asia :hoi JB males BMI >=30.0 (2019) Dh males BMI >=30.0 (2005) iubtotal (I-squared = 0.0%, p = 0.383)	RR (95% CI)	Weigl 3.88 3.88 13.15 0.38
tudy D sustralia aaksonen males BMI >= $30.0 (2019)$ ubtotal (l-squared = .%, p = .) ast Asia choi JB males BMI >= $30.0 (2019)$ bh males BMI >= $30.0 (2019)$ ubtotal (l-squared = 0.0% , p = 0.383) urope	RR (95% CI) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.77 (1.06, 1.30) 0.70 (0.22, 2.21) 1.17 (1.05, 1.29)	Weigl 3.88 3.88 13.15 0.38 13.53
tudy bustralia aaksonen males BMI >=30.0 (2019) ubtotal (I-squared = .%, p = .) ast Asia hoi JB males BMI >=30.0 (2019) bh males BMI >=30.0 (2019) ubtotal (I-squared = 0.0% , p = 0.383) urope laggstrom males BMI 30.8 (2010) arsson males BMI 30.0–34.9 (2007)	RR (95% CI) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.17 (1.06, 1.30) 0.70 (0.22, 2.21) 1.17 (1.05, 1.29) 1.13 (0.94, 1.35)	Weigl 3.88 3.88 13.15 0.38 13.53 8.35
tudy b ustralia aaksonen males BMI >=30.0 (2019) ubtotal (I-squared = .%, p = .) ast Asia ihoi JB males BMI >=30.0 (2019) bh males BMI >=30.0 (2005) ubtotal (I-squared = 0.0%, p = 0.383) urope laggstrom males BMI 30.8 (2010) arsson males BMI 30.0–34.9 (2007) arsson males BMI >=35 (2007)	RR (95% CI) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.17 (1.06, 1.30) 0.70 (0.22, 2.21) 1.17 (1.05, 1.29) 1.13 (0.94, 1.35) 0.92 (0.63, 1.35)	Weigl 3.88 3.88 13.15 0.38 13.53 8.35 2.89
tudy b ustralia aaksonen males $BMI >= 30.0 (2019)$ ubtotal (I-squared = .%, p = .) ast Asia hoi JB males $BMI >= 30.0 (2019)$ th males $BMI >= 30.0 (2019)$ th males $BMI >= 30.0 (2019)$ ubtotal (I-squared = 0.0%, p = 0.383) urope laggstrom males $BMI 30.8 (2010)$ arsson males $BMI 30.0 - 34.9 (2007)$ arsson males $BMI >= 35 (2007)$ eiba males $BMI >= 25.0 (2012)$	RR (95% Cl) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.17 (1.06, 1.30) 0.70 (0.22, 2.21) 1.17 (1.05, 1.29) 1.13 (0.94, 1.35) 0.92 (0.63, 1.35) 0.79 (0.29, 2.15)	Weigi 3.88 3.88 13.15 0.38 13.53 8.35 2.89 0.50
tudy b ustralia aaksonen males BMI >=30.0 (2019) ubtotal (I-squared = .%, p = .) ast Asia hoi JB males BMI >=30.0 (2019) ubtotal (I-squared = 0.0%, p = 0.383) urope laggstrom males BMI 30.8 (2010) arsson males BMI >=35 (2007) arsson males BMI >=35 (2017) app males BMI >=30.0 (2015)	RR (95% CI) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.17 (1.06, 1.30) 0.70 (0.22, 2.21) 1.17 (1.05, 1.29) 1.13 (0.94, 1.35) 0.92 (0.63, 1.35) 0.79 (0.29, 2.15) 1.36 (1.08, 1.72)	Weigi 3.88 3.88 13.15 0.38 13.53 8.35 2.89 0.50 6.19
tudy Ustralia aaksonen males BMI >=30.0 (2019) ubtotal (I-squared = .%, p = .) ast Asia hoi JB males BMI >=30.0 (2019) uh males BMI >=30.0 (2019) ubtotal (I-squared = 0.0%, p = 0.383) urope laggstrom males BMI 30.8 (2010) arsson males BMI 30.0–34.9 (2007) arsson males BMI >=35.0 (2012) app males BMI >=35.0 (2012) app males BMI >=320.0 (2005) oswall males BMI >=28.97 (2014)	RR (95% CI) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.17 (1.06, 1.30) 0.70 (0.22, 2.21) 1.17 (1.05, 1.29) 1.13 (0.94, 1.35) 0.92 (0.63, 1.35) 0.79 (0.29, 2.15) 1.36 (1.08, 1.72) 0.74 (0.45, 1.22)	Weigi 3.88 3.88 13.15 0.38 13.53 8.35 2.89 0.50 6.19 1.85
tudy b ustralia aaksonen males BMI >=30.0 (2019) ubtotal (I-squared = .%, p = .) ast Asia hoi JB males BMI >=30.0 (2019) bh males BMI >=30.0 (2019) ubtotal (I-squared = 0.0%, p = 0.383) urope laggstrom males BMI 30.8 (2010) arsson males BMI 30.0–34.9 (2007) arsson males BMI 30.0–34.9 (2007) arsson males BMI >=25.0 (2012) app males BMI >=25.0 (2012) app males BMI >=28.97 (2014) amanic males BMI >=28.97 (2014) amanic males BMI >=30.0 (2006)	RR (95% Cl) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.17 (1.06, 1.30) 0.70 (0.22, 2.21) 1.17 (1.05, 1.29) 1.13 (0.94, 1.35) 0.92 (0.63, 1.35) 0.79 (0.29, 2.15) 1.36 (1.08, 1.72) 1.36 (1.08, 1.72) 0.74 (0.45, 1.22) 1.25 (1.04, 1.50)	Weig 3.88 3.88 13.15 0.38 13.53 8.35 2.89 0.50 6.19 1.85 8.25
tudy bustralia aaksonen males BMI >=30.0 (2019) ubtotal (I-squared = .%, p = .) ast Asia hoi JB males BMI >=30.0 (2019) hh males BMI >=30.0 (2005) ubtotal (I-squared = 0.0%, p = 0.383) urope laggstrom males BMI 30.8 (2010) arsson males BMI 30.8 (2010) arsson males BMI >=35 (2007) eiba males BMI >=35 (2007) eiba males BMI >=35.0 (2012) app males BMI >=35.0 (2014) amanic males BMI >=30.0 (2006) ong males BMI 30–34.9 (2014)	RR (95% CI) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.17 (1.06, 1.30) 0.70 (0.22, 2.21) 1.17 (1.05, 1.29) 1.13 (0.94, 1.35) 0.92 (0.63, 1.35) 0.79 (0.29, 2.15) 1.36 (1.08, 1.72) 0.74 (0.45, 1.22) 1.25 (1.04, 1.50) 0.91 (0.76, 1.09)	Weig 3.88 3.88 13.15 0.38 13.53 13.53 8.35 2.89 0.50 6.19 1.85 8.25 8.39
tudy bustralia aaksonen males BMI >=30.0 (2019) ubtotal (I-squared = .%, p = .) ast Asia hoi JB males BMI >=30.0 (2019) h males BMI >=30.0 (2005) ubtotal (I-squared = 0.0%, p = 0.383) urope aggstrom males BMI 30.8 (2010) arsson males BMI 30.8 (2010) arsson males BMI >=35 (2007) eiba males BMI >=35 (2007) eiba males BMI >=35.0 (2012) app males BMI >=35.0 (2014) amanic males BMI >=35.0 (2014) ong males BMI >=35.0 (2014)	RR (95% Cl) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.17 (1.06, 1.30) 0.70 (0.22, 2.21) 1.17 (1.05, 1.29) 1.13 (0.94, 1.35) 0.92 (0.63, 1.35) 0.79 (0.29, 2.15) 1.36 (1.08, 1.72) 0.74 (0.45, 1.22) 1.25 (1.04, 1.50) 0.91 (0.76, 1.09) 1.47 (0.85, 2.53)	Weig 3.88 3.88 13.15 0.38 13.53 8.35 2.89 0.50 6.19 1.85 8.25 8.39 1.58
tudy D ustralia aaksonen males BMI >=30.0 (2019) ubtotal (I-squared = .%, p = .) ast Asia hoi JB males BMI >=30.0 (2019) th males BMI >=30.0 (2005) ubtotal (I-squared = 0.0%, p = 0.383) urope lagstrom males BMI 30.8 (2010) arsson males BMI >=35 (2007) eiba males BMI >=35.0 (2012) app males BMI >=28.97 (2014) amanic males BMI >=28.97 (2014) amanic males BMI >=30.0 (2005) oswall males BMI >=30.0 (2014) ong males BMI >=35.0 (2014) ong males BMI >=35.0 (2014) ong males BMI >=35.0 (2014)	RR (95% Cl) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.17 (1.06, 1.30) 0.70 (0.22, 2.21) 1.17 (1.05, 1.29) 1.13 (0.94, 1.35) 0.92 (0.63, 1.35) 0.79 (0.29, 2.15) 1.36 (1.08, 1.72) 0.74 (0.45, 1.22) 1.25 (1.04, 1.50) 0.91 (0.76, 1.09) 1.47 (0.85, 2.53) 1.91 (0.74, 4.95)	Weigi 3.88 3.88 13.15 0.38 13.53 8.35 2.89 0.50 6.19 1.85 8.25 8.25 8.39 1.58 0.55 3.44
tudy D sustralia aaksonen males BMI >=30.0 (2019) ubtotal (l-squared = .%, p = .) ast Asia hoi JB males BMI >=30.0 (2019) Dh males BMI >=30.0 (2019) Dh males BMI >=30.0 (2005) ubtotal (l-squared = 0.0%, p = 0.383) urope laggstrom males BMI 30.0-34.9 (2007) arsson males BMI >=35.0 (2012) lapp males BMI >=35.0 (2012) lapp males BMI >=35.0 (2014) amanic males BMI >=35.0 (2014) amanic males BMI >=35.0 (2014) ong males BMI >=35.0 (2014) Volk males BMI >=35.0 (2011) ubtotal (l-squared = 41.6%, p = 0.080)	RR (95% Cl) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.77 (1.06, 1.30) 0.70 (0.22, 2.21) 1.17 (1.05, 1.29) 1.13 (0.94, 1.35) 0.92 (0.63, 1.35) 0.79 (0.29, 2.15) 1.36 (1.08, 1.72) 0.74 (0.45, 1.22) 1.25 (1.04, 1.50) 0.91 (0.76, 1.09) 1.47 (0.85, 2.53) 1.91 (0.74, 4.95) 1.10 (0.78, 1.56)	Weigi 3.88 3.88 13.15 0.38 13.53 8.35 2.89 0.50 6.19 1.85 8.25 8.25 8.39 1.58 0.55 3.44
tudy bustralia aaksonen males BMI >=30.0 (2019) ubtotal (l-squared = .%, p = .) ast Asia hoi JB males BMI >=30.0 (2019) bh males BMI >=30.0 (2005) ubtotal (l-squared = 0.0%, p = 0.383) urope laggstrom males BMI 30.8 (2010) arsson males BMI 30.0–34.9 (2007) arsson males BMI 30.0–34.9 (2007) arsson males BMI >=35.0 (2012) app males BMI >=35.0 (2012) app males BMI >=35.0 (2014) amanic males BMI >=30.0 (2005) ooswall males BMI >=35.0 (2014) amanic males BMI >=35.0 (2014) wolk males BMI >=35.0 (2014) wolk males BMI >=30.0 (2001) ubtotal (l-squared = 41.6%, p = 0.080) IS/Canada	RR (95% Cl) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.77 (1.06, 1.30) 0.70 (0.22, 2.21) 1.17 (1.05, 1.29) 1.13 (0.94, 1.35) 0.92 (0.63, 1.35) 0.79 (0.29, 2.15) 1.36 (1.08, 1.72) 0.74 (0.45, 1.22) 1.25 (1.04, 1.50) 0.91 (0.76, 1.09) 1.47 (0.85, 2.53) 1.91 (0.74, 4.95) 1.10 (0.78, 1.56) 1.11 (0.97, 1.26)	Weigi 3.88 3.88 13.15 0.38 13.53 13.53 8.35 2.89 0.50 6.19 1.85 8.25 8.39 1.58 8.39 1.58 3.44 41.98
tudy bustralia aaksonen males BMI >= $30.0 (2019)$ ubtotal (I-squared = .%, p = .) ast Asia hoi JB males BMI >= $30.0 (2019)$ hh males BMI >= $30.0 (2005)$ ubtotal (I-squared = 0.0% , p = 0.383) urope laggstrom males BMI $30.8 (2010)$ arsson males BMI >= $35.0 (2007)$ arsson males BMI >= $35.0 (2007)$ arsson males BMI >= $35.0 (2007)$ app males BMI >= $35.0 (2007)$ app males BMI >= $35.0 (2005)$ oswall males BMI >= $35.0 (2005)$ ong males BMI >= $35.0 (2014)$ amanic males BMI >= $35.0 (2014)$ ong males BMI >= $35.0 (2014)$ Volk males BMI >= $35.0 (2011)$ ubtotal (I-squared = 41.6% , p = $0.080)$ IS/Canada indreotti males BMI $30.0-34.9 (2010)$	RR (95% Cl) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.17 (1.06, 1.30) 0.70 (0.22, 2.21) 1.17 (1.05, 1.29) 1.13 (0.94, 1.35) 0.92 (0.63, 1.35) 0.79 (0.29, 2.15) 1.36 (1.08, 1.72) 0.74 (0.45, 1.22) 1.25 (1.04, 1.50) 1.12 (0.74, 4.95) 1.10 (0.78, 1.56) 1.11 (0.97, 1.26) 1.41 (0.82, 2.42)	Weigi 3.88 3.88 13.15 0.38 13.53 13.53 8.35 2.89 0.50 6.19 1.85 8.25 8.29 1.58 0.55 3.44 41.98
tudy by ustralia aaksonen males $BMI >= 30.0 (2019)$ ubtotal (I-squared = .%, p = .) ast Asia hoi JB males $BMI >= 30.0 (2019)$ h males $BMI >= 30.0 (2005)$ ubtotal (I-squared = 0.0%, p = 0.383) urope aggstrom males $BMI 30.8 (2010)$ arsson males $BMI 30.0 - 34.9 (2007)$ arsson males $BMI >= 25.0 (2012)$ app males $BMI >= 25.0 (2012)$ app males $BMI >= 25.0 (2012)$ app males $BMI >= 28.97 (2014)$ ong males $BMI >= 35.0 (2014)$ /olk males $BMI >= 35.0 (2014)$ /olk males $BMI >= 35.0 (2014)$ /olk males $BMI >= 35.0 (2011)$ ubtotal (I-squared = 41.6%, p = 0.080) S/Canada ndreotti males $BMI >= 30 (2007)$	RR (95% Cl) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (0.22, 2.21) 1.17 (1.06, 1.30) 0.70 (0.22, 2.21) 1.17 (1.05, 1.29) 1.13 (0.94, 1.35) 0.92 (0.63, 1.35) 0.92 (0.63, 1.35) 0.79 (0.29, 2.15) 1.36 (1.08, 1.72) 0.74 (0.45, 1.22) 1.25 (1.04, 1.50) 0.91 (0.76, 1.09) 1.47 (0.85, 2.53) 1.91 (0.74, 4.95) 1.10 (0.78, 1.56) 1.11 (0.97, 1.26) 1.41 (0.82, 2.42) 1.01 (0.68, 1.50)	Weigi 3.88 3.88 13.15 0.38 13.53 13.53 8.35 2.89 0.50 6.19 1.85 8.25 8.39 1.58 0.55 3.44 41.98 1.60 2.77
tudy y ustralia aaksonen males BMI >=30.0 (2019) ubtotal (I-squared = .%, p = .) ast Asia hoi JB males BMI >=30.0 (2019) h males BMI >=30.0 (2005) ubtotal (I-squared = 0.0%, p = 0.383) urope aggstrom males BMI 30.8 (2010) arsson males BMI >=25.0 (2012) app males BMI >=35 (2007) aeiba males BMI >=35.0 (2012) app males BMI >=35.0 (2012) app males BMI >=35.0 (2014) ong males BMI >=35.0 (2014) ong males BMI >=35.0 (2014) /olk males BMI >=30.0 (2001) ubtotal (I-squared = 41.6%, p = 0.080) S/Canada ndreotti males BMI 30.0-34.9 (2010) olick males BMI >=30 (2007) oebnick males BMI >=34.9 (2008)	RR (95% Cl) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (0.22, 2.21) 1.17 (1.05, 1.29) 1.13 (0.94, 1.35) 0.92 (0.63, 1.35) 0.79 (0.29, 2.15) 1.36 (1.08, 1.72) 0.74 (0.45, 1.22) 1.25 (1.04, 1.50) 0.91 (0.76, 1.09) 1.47 (0.85, 2.53) 1.91 (0.74, 4.95) 1.10 (0.78, 1.56) 1.11 (0.97, 1.26) 1.41 (0.82, 2.42) 1.01 (0.68, 1.50) 1.21 (1.03, 1.43)	Weigi 3.88 3.88 13.15 0.38 13.53 13.53 8.35 2.89 0.50 6.19 1.85 8.39 1.58 8.39 1.58 8.39 1.58 3.44 41.98 1.60 2.77 9.23
tudy ustralia aaksonen males BMI >=30.0 (2019) ubtotal (I-squared = .%, p = .) ast Asia hoi JB males BMI >=30.0 (2019) h males BMI >=30.0 (2005) ubtotal (I-squared = 0.0%, p = 0.383) urope aggstrom males BMI 30.8 (2010) arsson males BMI >=35 (2007) airsson males BMI >=35 (2007) airsson males BMI >=35 (2012) app males BMI >=35.0 (2012) app males BMI >=35.0 (2014) ong males BMI >=35.0 (2014) /olk males BMI >=35.0 (2010) ubtotal (I-squared = 41.6%, p = 0.080) S/Canada ndreotti males BMI 30.0-34.9 (2010) olick males BMI >=35.0 (2007) oebnick males BMI >=35.0 (2008)	RR (95% Cl) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.71 (1.06, 1.30) 0.70 (0.22, 2.21) 1.17 (1.05, 1.29) 1.13 (0.94, 1.35) 0.92 (0.63, 1.35) 0.79 (0.29, 2.15) 1.36 (1.08, 1.72) 0.74 (0.45, 1.22) 1.25 (1.04, 1.50) 0.91 (0.76, 1.09) 1.47 (0.85, 2.53) 1.91 (0.74, 4.95) 1.10 (0.78, 1.56) 1.11 (0.97, 1.26) 1.11 (0.97, 1.26) 1.41 (0.82, 2.42) 1.01 (0.68, 1.50) 1.21 (1.03, 1.43) 1.25 (0.96, 1.63)	Weigi 3.88 3.88 13.15 0.38 13.53 13.53 8.35 2.89 0.50 6.19 1.85 8.25 8.39 1.58 0.55 0.55 0.55 3.44 41.98 1.60 2.77 9.23 5.19
tudy ustralia aaksonen males BMI >=30.0 (2019) ubtotal (I-squared = .%, p = .) ast Asia hoi JB males BMI >=30.0 (2019) h males BMI >=30.0 (2005) ubtotal (I-squared = 0.0%, p = 0.383) urope aggstrom males BMI 30.8 (2010) arsson males BMI >=35.0 (2007) arsson males BMI >=35.0 (2007) arsson males BMI >=35.0 (2005) oswall males BMI >=28.97 (2014) amanic males BMI >=28.97 (2014) amanic males BMI >=28.97 (2014) amanic males BMI >=35.0 (2006) ong males BMI >=35.0 (2001) ubtotal (I-squared = 41.6%, p = 0.080) S/Canada ndreotti males BMI 30.0-34.9 (2010) olick males BMI >=30.0 (2007) oebnick males BMI >=30.0 (2008) oebnick males BMI >=30.0 (2004)	RR (95% Cl) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.71 (1.06, 1.30) 0.70 (0.22, 2.21) 1.17 (1.05, 1.29) 1.13 (0.94, 1.35) 0.92 (0.63, 1.35) 0.79 (0.29, 2.15) 1.36 (1.08, 1.72) 0.74 (0.45, 1.22) 1.25 (1.04, 1.50) 1.91 (0.74, 4.95) 1.10 (0.78, 1.56) 1.11 (0.97, 1.26) 1.11 (0.97, 1.26) 1.11 (0.82, 2.42) 1.01 (0.68, 1.50) 1.21 (1.03, 1.43) 1.25 (0.96, 1.63) 0.85 (0.67, 1.08)	Weigi 3.88 3.88 13.15 0.38 13.53 13.53 8.35 2.89 0.50 6.19 1.85 8.25 8.39 1.85 8.25 8.39 1.58 0.55 3.44 41.98 1.60 2.77 9.23 5.19 5.99
tudy bustralia aaksonen males BMI >=30.0 (2019) ubtotal (l-squared = .%, p = .) ast Asia hoi JB males BMI >=30.0 (2019) wh males BMI >=30.0 (2005) ubtotal (l-squared = 0.0%, p = 0.383) urope laggstrom males BMI 30.0 = 34.9 (2007) arsson males BMI >=35.0 (2012) app males BMI >=35.0 (2012) app males BMI >=35.0 (2012) app males BMI >=35.0 (2014) amanic males BMI >=30.0 (2004) ibtotal (l-squared = 41.6%, p = 0.080) IS/Canada ndreotti males BMI 30.0 = 34.9 (2010) lolick males BMI >=35.0 (2007) oebnick males BMI >=35.0 (2008) oebnick males BMI >=35.0 (2004) amanic black males BMI >=30.0 (2004) amanic white males BMI >=30.0 (2004)	RR (95% Cl) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.71 (1.05, 1.20) 1.13 (0.94, 1.35) 0.92 (0.63, 1.35) 0.79 (0.29, 2.15) 1.36 (1.08, 1.72) 0.74 (0.45, 1.22) 1.72 (1.04, 1.50) 0.91 (0.76, 1.09) 1.47 (0.85, 2.53) 1.91 (0.74, 4.95) 1.10 (0.78, 1.56) 1.11 (0.97, 1.26) 1.41 (0.82, 2.42) 1.01 (0.68, 1.50) 1.25 (1.04, 1.33) 1.25 (0.96, 1.63) 0.85 (0.67, 1.08) 1.13 (1.06, 1.20)	Weigi 3.88 3.88 13.15 0.38 13.53 13.53 8.35 2.89 0.50 6.19 1.85 8.25 8.39 1.58 0.55 3.44 41.98 1.60 2.77 9.23 5.19 5.59 15.83
tudy bustralia aaksonen males BMI >=30.0 (2019) ubtotal (l-squared = .%, p = .) ast Asia hoi JB males BMI >=30.0 (2019) bh males BMI >=30.0 (2019) bh males BMI >=30.0 (2005) ubtotal (l-squared = 0.0%, p = 0.383) urope laggstrom males BMI 30.0–34.9 (2007) arsson males BMI >=35.0 (2012) app males BMI >=35.0 (2012) app males BMI >=35.0 (2014) amanic males BMI >=35.0 (2014) amanic males BMI >=35.0 (2014) wolk males BMI >=35.0 (2011) ubtotal (l-squared = 41.6%, p = 0.080)	RR (95% Cl) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.71 (1.06, 1.30) 0.70 (0.22, 2.21) 1.17 (1.05, 1.29) 1.13 (0.94, 1.35) 0.92 (0.63, 1.35) 0.79 (0.29, 2.15) 1.36 (1.08, 1.72) 0.74 (0.45, 1.22) 1.25 (1.04, 1.50) 1.91 (0.74, 4.95) 1.10 (0.78, 1.56) 1.11 (0.97, 1.26) 1.11 (0.97, 1.26) 1.11 (0.82, 2.42) 1.01 (0.68, 1.50) 1.21 (1.03, 1.43) 1.25 (0.96, 1.63) 0.85 (0.67, 1.08)	Weigi 3.88 3.88 13.15 0.38 13.53 13.53 8.35 2.89 0.50 6.19 1.85 8.25 8.39 1.85 8.25 8.39 1.58 0.55 3.44 41.98 1.60 2.77 9.23 5.19 5.99
udy ustralia haksonen males BMI >=30.0 (2019) ubtotal (I-squared = .%, p = .) hast Asia hoi JB males BMI >=30.0 (2019) h males BMI >=30.0 (2005) ubtotal (I-squared = 0.0%, p = 0.383) urope aggstrom males BMI 30.8 (2010) rrsson males BMI >=35.0 (2007) reiba males BMI >=35.0 (2012) app males BMI >=35.0 (2014) amanic males BMI >=35.0 (2014) ong males BMI >=35.0 (2014) holt males BMI >=35.0 (2014) social (I-squared = 41.6%, p = 0.080) S/Canada ndreotti males BMI 30.0-34.9 (2010) olick males BMI 30.0-34.9 (2010) olick males BMI >=35.0 (2008) bebnick males BMI >=35.0 (2004) amanic black males BMI >=30.0 (2004) amanic white males BMI >=30.0 (2004)	RR (95% Cl) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.71 (1.05, 1.20) 1.13 (0.94, 1.35) 0.92 (0.63, 1.35) 0.79 (0.29, 2.15) 1.36 (1.08, 1.72) 0.74 (0.45, 1.22) 1.72 (1.04, 1.50) 0.91 (0.76, 1.09) 1.47 (0.85, 2.53) 1.91 (0.74, 4.95) 1.10 (0.78, 1.56) 1.11 (0.97, 1.26) 1.41 (0.82, 2.42) 1.01 (0.68, 1.50) 1.25 (1.04, 1.33) 1.25 (0.96, 1.63) 0.85 (0.67, 1.08) 1.13 (1.06, 1.20)	Weig 3.88 3.88 13.15 0.38 13.53 13.53 8.35 2.89 0.50 6.19 1.85 8.39 1.58 3.44 41.98 1.60 2.77 9.23 5.19 5.99 15.83 40.61
udy ustralia taksonen males BMI >=30.0 (2019) ubtotal (I-squared = .%, p = .) ast Asia hoi JB males BMI >=30.0 (2019) h males BMI >=30.0 (2005) ubtotal (I-squared = 0.0%, p = 0.383) urope aggstrom males BMI 30.8 (2010) trsson males BMI >=25.0 (2012) app males BMI >=25.0 (2012) app males BMI >=25.0 (2012) app males BMI >=25.0 (2012) app males BMI >=35.0 (2014) folk males BMI >=35.0 (2014) folk males BMI >=35.0 (2014) folk males BMI >=35.0 (2014) folk males BMI >=35.0 (2010) ubtotal (I-squared = 41.6%, p = 0.080) S/Canada ndreotti males BMI >=30.0 (2004) amanic white males B	RR (95% Cl) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (1.23, 2.34) 1.70 (0.22, 2.21) 1.17 (1.06, 1.30) 0.70 (0.22, 2.21) 1.17 (1.05, 1.29) 1.13 (0.94, 1.35) 0.92 (0.63, 1.35) 0.79 (0.29, 2.15) 1.36 (1.08, 1.72) 0.74 (0.45, 1.22) 1.25 (1.04, 1.50) 0.91 (0.76, 1.09) 1.47 (0.85, 2.53) 1.91 (0.78, 1.56) 1.11 (0.97, 1.26) 1.41 (0.82, 2.42) 1.01 (0.68, 1.50) 1.21 (1.03, 1.43) 1.25 (0.96, 1.63) 0.85 (0.67, 1.08) 1.13 (1.06, 1.20) 1.12 (1.01, 1.24)	Weig 3.88 3.88 13.15 0.38 13.53 13.53 8.35 2.89 0.50 6.19 1.85 8.25 8.39 1.58 0.55 3.44 41.98 1.60 2.77 9.23 5.19 5.99 15.83

Figure 1. A: Forest plot presenting the association between overweight and bladder cancer risk in males. Studies are subgrouped by geographical region. **B:** Forest plot presenting the association between obesity and bladder cancer risk in males. Studies are subgrouped by geographical region.

С

D

Study ID		% Weight
Australia I		
Laaksonen females BMI 25.0–29.9 (2019)	1.30 (0.92, 1.83)	7.05
Subtotal (I–squared = .%, p = .)	1.30 (0.92, 1.83)	7.05
East Asia		
Jee females BMI 25.0–29.9 (2008)	1.10 (0.75, 1.62) 5.	5.84
Subtotal (I-squared = .%, p = .)		5.84
Europe Haggstrom females BMI 26.4 (2010)	0.67 (0.44, 1.03) 4.	4.93
Rapp females BMI 25.0–29.9 (2005)		2.61
Reeves females BMI 25–27.4 (2007)		19.24
Reeves females BMI 27.5–29.5 (2007)		14.55
Roswall females BMI 25.01–28.02 (2014)		9.28
Song females BMI 25.0–27.4 (2014)		0.60
Song females BMI 27.5–29.9 (2014)		0.57
Subtotal (I–squared = 41.0%, p = 0.118)		51.78
. 		
US/Canada I Andreotti females BMI 25.0–29.9 (2010)	0.97 (0.32, 2.91) 0.	0.83
Cantwell females BMI 25.–29.9 (2016)		6.53
Holick females BMI 25.–26.9 (2007)		8.11
Holick females BMI 27.0–29.9 (2007)		6.17
Koebnick females BMI 25.0–29.9 (2008)		8.36
Tripathi females BMI 25.04–27.43 (2002)		2.71
Tripathi females BMI 27.46–30.67 (2002)		2.62
Subtotal (I–squared = 0.0%, p = 0.473)		35.33
	106 (0.06, 1.17)	100.00
Overall (I-squared = 18.0%, p = 0.248)	1.06 (0.96, 1.17)	100.00
NOTE: Weights are from random effects analysis		
.0982 1 Study	10.2	%
Study	96	% Weight
Study ID Australia	% RR (95% CI) W	Weight
Study ID Australia	% RR (95% CI) W	
Study ID Australia Laaksonen females BMI >=30.0 (2019)	% RR (95% CI) ₩ • 2.03 (1.42, 2.90) 9.	Weigh
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I–squared = .%, p = .)	% RR (95% CI) ₩ • 2.03 (1.42, 2.90) 9.	Weight 9.31
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I–squared = .%, p = .) East Asia	% RR (95% Cl) W 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9.	Weight 9.31 9.31
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I–squared = .%, p = .) East Asia Jee females BMI >=30.0 (2008)	% RR (95% Cl) ₩ 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. - 0.74 (0.27, 2.04) 1.	Weight 9.31 9.31 1.95
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I–squared = .%, p = .) East Asia	 % RR (95% Cl) 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 0.74 (0.27, 2.04) 1. 	Weigh 9.31 9.31
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I–squared = .%, p = .) East Asia Jee females BMI >=30.0 (2008)	% RR (95% Cl) ₩ 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. - 0.74 (0.27, 2.04) 1.	Weigh 9.31 9.31 1.95
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I-squared = .%, p = .) East Asia Jee females BMI >=30.0 (2008) Subtotal (I-squared = .%, p = .) Europe	RR (95% CI) W 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 0.74 (0.27, 2.04) 1. 0.74 (0.27, 2.04) 1.	Weigh 9.31 9.31 1.95
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I–squared = .%, p = .) East Asia Jee females BMI >=30.0 (2008) Subtotal (I–squared = .%, p = .) Europe Haggstrom females BMI 31.7 (2010) Rapp females BMI >=30.0 (2005)	RR (95% CI) W 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 0.74 (0.27, 2.04) 1. 0.74 (0.27, 2.04) 1. 0.87 (0.58, 1.31) 7.	Weigh 9.31 9.31 1.95 1.95
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I–squared = .%, p = .) East Asia Jee females BMI >=30.0 (2008) Subtotal (I–squared = .%, p = .) Europe Haggstrom females BMI 31.7 (2010) Rapp females BMI >=30.0 (2005)	RR (95% CI) W 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 0.74 (0.27, 2.04) 1. 0.74 (0.27, 2.04) 1. 0.87 (0.58, 1.31) 7. 1.60 (0.76, 3.36) 3.	Weigh 9.31 9.31 1.95 1.95 7.93
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I–squared = .%, p = .) East Asia Jee females BMI >=30.0 (2008) Subtotal (I–squared = .%, p = .) Europe Haggstrom females BMI 31.7 (2010) Rapp females BMI >=30.0 (2005) Reeves females BMI >=30 (2007)	RR (95% CI) W 2.03 (1.42, 2.90) 9, 2.03 (1.42, 2.90) 9, 2.03 (1.42, 2.90) 9, 0.74 (0.27, 2.04) 1, 0.74 (0.27, 2.04) 1, 0.87 (0.58, 1.31) 7, 1.60 (0.76, 3.36) 3, 1.07 (0.88, 1.30) 14	Weigh 9.31 9.31 1.95 1.95 7.93 3.36
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I–squared = .%, p = .) East Asia Jee females BMI >=30.0 (2008) Subtotal (I–squared = .%, p = .) Europe Haggstrom females BMI 31.7 (2010) Rapp females BMI >=30.0 (2005) Reeves females BMI >=30.0 (2007) Roswall females BMI >=28.03 (2014)	RR (95% Cl) W 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 0.74 (0.27, 2.04) 1. 0.74 (0.27, 2.04) 1. 0.87 (0.58, 1.31) 7. 1.60 (0.76, 3.36) 3. 1.07 (0.88, 1.30) 14 0.91 (0.68, 1.22) 12	Weigh 9.31 9.31 1.95 1.95 7.93 3.36 14.85
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I–squared = .%, p = .) East Asia Jee females BMI >=30.0 (2008) Subtotal (I–squared = .%, p = .) Europe Haggstrom females BMI 31.7 (2010) Rapp females BMI >=30.0 (2005) Reeves females BMI >=30.0 (2007) Roswall females BMI >=30.0 (2014) Song females BMI >=35.0 (2014)	RR (95% Cl) W 2.03 (1.42, 2.90) 9, 2.03 (1.42, 2.90) 9, 2.03 (1.42, 2.90) 9, 0.74 (0.27, 2.04) 1. 0.74 (0.27, 2.04) 1. 0.87 (0.58, 1.31) 7, 1.60 (0.76, 3.36) 3, 1.07 (0.88, 1.30) 14 0.91 (0.68, 1.22) 17 2.63 (0.69, 10.01) 1.	Weigh 9.31 9.31 1.95 1.95 7.93 3.36 14.85 11.15
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I–squared = .%, p = .) East Asia Jee females BMI >=30.0 (2008) Subtotal (I–squared = .%, p = .) Europe Haggstrom females BMI 31.7 (2010) Rapp females BMI >=30.0 (2005) Reeves females BMI >=30.0 (2007) Roswall females BMI >=30.0 (2014) Song females BMI >=35.0 (2014)	RR (95% Cl) W 2.03 (1.42, 2.90) 9, 2.03 (1.42, 2.90) 9, 2.03 (1.42, 2.90) 9, 0.74 (0.27, 2.04) 1, 0.74 (0.27, 2.04) 1, 0.87 (0.58, 1.31) 7, 1.60 (0.76, 3.36) 3, 1.07 (0.88, 1.30) 14, 0.91 (0.68, 1.22) 17, 2.63 (0.69, 10.01) 1, 1.93 (0.32, 11.66) 0,	Weigh 9.31 9.31 1.95 1.95 7.93 3.36 14.85 11.15 1.17
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I–squared = .%, p = .) East Asia Jee females BMI >=30.0 (2008) Subtotal (I–squared = .%, p = .) Europe Haggstrom females BMI 31.7 (2010) Rapp females BMI >=30.0 (2005) Reeves females BMI >=30.0 (2007) Roswall females BMI >=30.0 (2014) Song females BMI >=35.0 (2014) Song females BMI >=35.0 (2014) Wolk females BMI >=36.6 (2001)	RR (95% Cl) W 2.03 (1.42, 2.90) 9, 2.03 (1.42, 2.90) 9, 2.03 (1.42, 2.90) 9, 0.74 (0.27, 2.04) 1, 0.74 (0.27, 2.04) 1, 0.87 (0.58, 1.31) 7, 1.60 (0.76, 3.36) 3, 1.07 (0.88, 1.30) 14, 0.91 (0.68, 1.22) 17, 2.63 (0.69, 10.01) 1, 1.93 (0.32, 11.66) 0, 1.20 (0.95, 1.52) 1, 1.20 (0.95, 1.52) 1, 1.2	Weigh 9.31 9.31 1.95 1.95 7.93 3.36 14.85 11.15 1.17 0.67
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I–squared = .%, p = .) East Asia Jee females BMI >=30.0 (2008) Subtotal (I–squared = .%, p = .)	RR (95% Cl) W 2.03 (1.42, 2.90) 9, 2.03 (1.42, 2.90) 9, 2.03 (1.42, 2.90) 9, 0.74 (0.27, 2.04) 1, 0.74 (0.27, 2.04) 1, 0.74 (0.27, 2.04) 1, 0.87 (0.58, 1.31) 7, 1.60 (0.76, 3.36) 3, 1.07 (0.88, 1.30) 14 0.91 (0.68, 1.22) 17 2.63 (0.69, 10.01) 1, 1.93 (0.32, 11.66) 0, 1.20 (0.95, 1.52) 13	Weigh 9.31 9.31 1.95 1.95 7.93 3.36 14.85 11.15 1.17 0.67 13.32
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I-squared = .%, p = .) East Asia Jee females BMI >=30.0 (2008) Subtotal (I-squared = .%, p = .) Europe Haggstrom females BMI 31.7 (2010) Rapp females BMI >=30.0 (2005) Reeves females BMI >=30.0 (2007) Roswall females BMI >=28.03 (2014) Song females BMI >=28.03 (2014) Wolk females BMI >=28.6 (2001) Subtotal (I-squared = 4.8%, p = 0.390)	RR (95% Cl) W 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 0.74 (0.27, 2.04) 1. 0.74 (0.27, 2.04) 1. 0.87 (0.58, 1.31) 7. 1.60 (0.76, 3.36) 3. 1.07 (0.88, 1.30) 14. 0.91 (0.68, 1.22) 17. 2.63 (0.69, 10.01) 1. 1.93 (0.32, 11.66) 0. 1.20 (0.95, 1.52) 13. 1.08 (0.94, 1.23) 52.	Weigh 9.31 9.31 1.95 1.95 7.93 3.36 14.85 11.15 1.17 0.67 13.32
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I-squared = .%, p = .) East Asia Jee females BMI >=30.0 (2008) Subtotal (I-squared = .%, p = .) Europe Haggstrom females BMI 31.7 (2010) Rapp females BMI >=30.0 (2005) Reeves females BMI >=30.0 (2007) Roswall females BMI >=28.03 (2014) Song females BMI >=28.03 (2014) Song females BMI >=28.0 (2014) Song females BMI >=28.0 (2014) Song females BMI >=28.0 (2014) Subtotal (I-squared = 4.8%, p = 0.390) US/Canada	RR (95% CI) W 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 0.74 (0.27, 2.04) 1. 0.74 (0.27, 2.04) 1. 0.74 (0.27, 2.04) 1. 0.87 (0.58, 1.31) 7. 1.60 (0.76, 3.36) 3. 1.07 (0.88, 1.30) 14 0.91 (0.68, 1.22) 17 2.63 (0.69, 10.01) 1. 1.93 (0.32, 11.66) 0. 1.20 (0.95, 1.52) 13 1.08 (0.94, 1.23) 55	Weigh 9.31 9.31 1.95 1.95 7.93 3.36 14.85 11.15 1.17 0.67 13.32 52.45
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I–squared = .%, p = .) Europe Haggstrom females BMI >=30.0 (2008) Subtotal (I–squared = .%, p = .) Europe Haggstrom females BMI >=30.0 (2005) Reeves females BMI >=30.0 (2005) Reeves females BMI >=30.0 (2007) Roswall females BMI >=30.0 (2007) Roswall females BMI >=30.0 (2014) Song females BMI >=28.03 (2014) Song females BMI >=35.0 (2014) Subtotal (I–squared = 4.8%, p = 0.390) US/Canada Cantwell females BMI 30–34.9 (2006) Cantwell females BMI 3–35 (2006)	RR (95% CI) W 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 0.74 (0.27, 2.04) 1. 0.74 (0.27, 2.04) 1. 0.74 (0.27, 2.04) 1. 0.87 (0.58, 1.31) 7. 1.60 (0.76, 3.36) 3. 1.07 (0.88, 1.30) 14 0.91 (0.68, 9, 10.01) 1. 1.93 (0.32, 11.66) 0. 1.20 (0.95, 1.52) 13 1.08 (0.94, 1.23) 52 1.28 (0.73, 2.25) 5. 0.83 (0.26, 2.64) 1.	Weigh 9.31 9.31 1.95 1.95 7.93 3.36 14.85 11.15 1.17 0.67 13.32 52.45 5.20
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I–squared = .%, p = .) Europe Haggstrom females BMI >=30.0 (2008) Subtotal (I–squared = .%, p = .) Europe Haggstrom females BMI >=30.0 (2005) Reeves females BMI >=30.0 (2007) Roswall females BMI >=30.0 (2007) Roswall females BMI >=35.0 (2014) Song females BMI >=35.0 (2014) Song females BMI >=35.0 (2014) Wolk females BMI >=35.0 (2014) US/Canada Cantwell females BMI 30–34.9 (2006) Cantwell females BMI >=30 (2007) Holick females BMI >=30 (2007)	RR (95% Cl) W 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 0.74 (0.27, 2.04) 1. 0.74 (0.27, 2.04) 1. 0.87 (0.58, 1.31) 7. 1.60 (0.76, 3.36) 3. 1.07 (0.88, 1.30) 14 0.91 (0.68, 1.22) 11 2.63 (0.69, 10.01) 1. 1.93 (0.32, 11.66) 0. 1.20 (0.95, 1.52) 13 1.08 (0.94, 1.23) 52 0.83 (0.26, 2.64) 1. 1.31 (0.91, 1.89) 9.	Weigh 9.31 9.31 1.95 1.95 7.93 3.36 14.85 11.15 1.17 0.67 13.32 52.45 5.20 1.54
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I-squared = .%, p = .) Europe Haggstrom females BMI >=30.0 (2008) Subtotal (I-squared = .%, p = .) Europe Haggstrom females BMI >=30.0 (2005) Reeves females BMI >=30.0 (2005) Reeves females BMI >=30.0 (2007) Roswall females BMI >=30.0 (2014) Song females BMI >=28.0 (2014) Subtotal (I-squared = 4.8%, p = 0.390) US/Canada Cantwell females BMI 30–34.9 (2006)	RR (95% Cl) W 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 0.74 (0.27, 2.04) 1. 0.74 (0.27, 2.04) 1. 0.87 (0.58, 1.31) 7. 1.60 (0.76, 3.36) 3. 1.07 (0.88, 1.30) 14 0.91 (0.68, 1.22) 11 2.63 (0.69, 10.01) 1. 1.93 (0.32, 11.66) 0. 1.20 (0.95, 1.52) 13 1.08 (0.94, 1.23) 52 0.83 (0.26, 2.64) 1. 1.31 (0.91, 1.89) 9. 1.38 (0.97, 1.97) 9.	Weigh 9.31 9.31 1.95 1.95 7.93 3.36 14.85 11.15 1.17 0.67 13.32 52.45 5.20 1.54 9.08
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I–squared = .%, p = .) East Asia Jee females BMI >=30.0 (2008) Subtotal (I–squared = .%, p = .) Europe Haggstrom females BMI >=30.0 (2005) Reeves females BMI >=30.0 (2005) Reeves females BMI >=30.0 (2007) Roswall females BMI >=30.0 (2007) Roswall females BMI >=35.0 (2014) Song females BMI >=35.0 (2014) Wolk females BMI >=35.0 (2014) US/Canada Cantwell females BMI 30–34.9 (2006) Cantwell females BMI 30–34.9 (2006) Cantwell females BMI 30–34.9 (2006) Cantwell females BMI >=35 (2007) Koebnick females BMI 30–34.9 (2008) Koebnick females BMI >=35.0 (2008)	RR (95% Cl) W 2.03 (1.42, 2.90) 9, 2.03 (1.42, 2.90) 9, 2.03 (1.42, 2.90) 9, 2.03 (1.42, 2.90) 9, 0.74 (0.27, 2.04) 1, 0.74 (0.27, 2.04) 1, 0.74 (0.27, 2.04) 1, 0.74 (0.27, 2.04) 1, 1.60 (0.76, 3.36) 3, 1.07 (0.88, 1.30) 14 0.91 (0.68, 1.22) 11 2.63 (0.69, 10.01) 1, 1.93 (0.32, 11.66) 0, 1.20 (0.95, 1.52) 13 1.08 (0.94, 1.23) 55 0.83 (0.26, 2.64) 1, 1.31 (0.91, 1.89) 9, 1.38 (0.97, 1.97) 9, 1.37 (0.87, 2.17) 6,	Weigh 9.31 9.31 1.95 1.95 7.93 3.36 14.85 11.15 1.17 0.67 13.32 52.45 5.20 1.54 9.08 9.31
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I–squared = .%, p = .) East Asia Jee females BMI >=30.0 (2008) Subtotal (I–squared = .%, p = .) Europe Haggstrom females BMI 31.7 (2010) Rapp females BMI >=30.0 (2005) Reeves females BMI >=30.0 (2007) Rosvall females BMI >=30.0 (2007) Rosvall females BMI >=35.0 (2014) Song females BMI >=35.0 (2014) Song females BMI >=35.0 (2014) Subtotal (I–squared = 4.8%, p = 0.390) US/Canada Cantwell females BMI 30–34.9 (2006) Cantwell females BMI >=30 (2007) Koebnick females BMI 30–34.9 (2008)	RR (95% Cl) W 2.03 (1.42, 2.90) 9, 2.03 (1.42, 2.90) 9, 2.03 (1.42, 2.90) 9, 2.03 (1.42, 2.90) 9, 0.74 (0.27, 2.04) 1, 0.74 (0.27, 2.04) 1, 0.74 (0.27, 2.04) 1, 0.87 (0.58, 1.31) 7, 1.60 (0.76, 3.36) 3, 1.07 (0.88, 1.30) 14, 0.91 (0.68, 1.22) 17, 2.63 (0.69, 10.01) 1, 1.93 (0.32, 11.66) 0, 1.20 (0.95, 1.52) 13, 1.08 (0.94, 1.23) 55, 1.28 (0.73, 2.25) 5, 0.83 (0.26, 2.64) 1, 1.31 (0.91, 1.89) 9, 1.38 (0.97, 1.97) 9, 1.37 (0.87, 2.17) 6, 0.63 (0.33, 1.20) 4,	Weigh 9.31 9.31 1.95 1.95 7.93 3.36 14.85 11.15 1.17 0.67 13.32 52.45 5.20 1.54 9.08 9.31 6.90
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I–squared = .%, p = .) East Asia Jee females BMI >=30.0 (2008) Subtotal (I–squared = .%, p = .) Europe Haggstrom females BMI >=30.0 (2005) Reeves females BMI >=30.0 (2007) Roswall females BMI >=35.0 (2014) Song females BMI >=35.0 (2014) Song females BMI >=35.0 (2014) Subtotal (I–squared = 4.8%, p = 0.390) US/Canada Cantwell females BMI >=35 (2006) Holick females BMI >=35 (2007) Koebnick females BMI >=35 (2008) Koebnick females BMI >=35.0 (2008) Koebnick females BMI >=35.0 (2008) Koebnick females BMI >=35.0 (2008) Tripathi females BMI >=35.0 (2008) Tripathi females BMI >=35.0 (2002) Subtotal (I–squared = 6.9%, p = 0.373)	RR (95% Cl) 2.03 (1.42, 2.90) 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 0.74 (0.27, 2.04) 1. 0.74 (0.27, 2.04) 1. 0.87 (0.58, 1.31) 7. 1.60 (0.76, 3.36) 3. 1.07 (0.88, 1.30) 1. 0.91 (0.68, 1.22) 1. 1.93 (0.32, 11.66) 1.20 (0.95, 1.52) 1. 1.08 (0.73, 2.25) 5. 0.83 (0.26, 2.64) 1. 1.31 (0.91, 1.89) 9. 1.38 (0.97, 1.97) 9. 1.37 (0.87, 2.17) 6. 0.63 (0.33, 1.20) 4. 1.23 (1.00, 1.51) 3. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	Weigh 9.31 9.31 1.95 1.95 7.93 3.36 14.85 11.15 1.17 0.67 13.32 52.45 5.20 1.54 9.08 9.31 6.90 4.26 36.29
Study ID Australia Laaksonen females BMI >=30.0 (2019) Subtotal (I–squared = .%, p = .) East Asia Jee females BMI >=30.0 (2008) Subtotal (I–squared = .%, p = .) Europe Haggstrom females BMI >=30.0 (2005) Reeves females BMI >=30.0 (2005) Reeves females BMI >=30.0 (2007) Roswall females BMI 30–34.9 (2014) Song females BMI >=35.0 (2014) Wolk females BMI >=35.0 (2014) US/Canada Cantwell females BMI 30–34.9 (2006) Cantwell females BMI 30–34.9 (2006) Cantwell females BMI 30–34.9 (2008) Koebnick females BMI >=35.0 (2008) Tripathi females BMI >=35.0 (2002)	RR (95% Cl) 2.03 (1.42, 2.90) 2.03 (1.42, 2.90) 9. 2.03 (1.42, 2.90) 9. 0.74 (0.27, 2.04) 1. 0.74 (0.27, 2.04) 1. 0.87 (0.58, 1.31) 7. 1.60 (0.76, 3.36) 3. 1.07 (0.88, 1.30) 1. 0.91 (0.68, 1.22) 1. 1.93 (0.32, 11.66) 1.20 (0.95, 1.52) 1. 1.08 (0.73, 2.25) 5. 0.83 (0.26, 2.64) 1. 1.31 (0.91, 1.89) 9. 1.38 (0.97, 1.97) 9. 1.37 (0.87, 2.17) 6. 0.63 (0.33, 1.20) 4. 1.23 (1.00, 1.51) 3. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	Weigh 9.31 9.31 1.95 1.95 7.93 3.36 14.85 11.15 0.67 13.32 52.45 5.20 1.54 9.08 9.31 6.90 4.26

Figure 1. C: Forest plot presenting the association between overweight and bladder cancer risk in females. Studies are subgrouped by geographical region. **D**: Forest plot presenting the association between obesity and bladder cancer risk in females. Studies are subgrouped by geographical region.

Subgroup analyses were performed to examine the association of overweight/obese status in men and women with bladder cancer across geographical regions. Pooled analysis of studies for overweight men, revealed a persistent significant increased risk in Australia (pooled RR=1.51, 95%) CI: 1.15-1.98) with 1 study arm, in East Asia (pooled) RR=1.19, 95% CI: 1.15-1.23) with 3 study arms and in US/ Canada (pooled RR=1.19, 95% CI: 1.07-1.32) with 4 study arms, while in Europe the association in risk didn't persist (pooled RR=1.06, 95% CI: 0.95-1.18) (Figure 1A). In a similar fashion, pooled analysis of studies for obese men revealed a persistent significant increased risk in Australia (pooled RR=1.70, 95% CI: 1.23-1.34) with 1 study arm, in East Asia (pooled RR=1.17, 95% CI: 1.05-1.29) with 2 study arms and in US/ Canada (pooled RR=1.12, 95% CI: 1.01-1.24) with 6 study arms, while in Europe significant risk was not detected (pooled RR=1.11, 95% CI: 0.97-1.26) (Figure 1B). Regarding overweight women, pooled analysis did not reveal any significant increased risk in any geographical region (Figure 1C), while for obese women a significantly increased risk persisted for Australia (pooled RR=2.02, 95% CI: 1.42-2.90) with 1 study arm, while in the remaining regions no significant difference was detected (Figure 1D).

Subgroup analyses by mean age

Pooled analysis of 7 study arms revealed that overweight men \geq 50 years old showed a significant increased risk (pooled RR=1.17, 95% CI: 1.08-1.27), while overweight men <50 years old and overweight women of any age did not show any difference from normal weight individuals (Supplemental Figures 2A, 2B). Similarly, only obese men aged \geq 50 years old showed a significant increased risk (pooled RR=1.18, 95% CI: 1.08-1.29) in a pooled analysis of 8 study arms, while obese men <50 years old and obese women of any age did not show any increased risk (Supplemental Figures 2C, 2D).

Subgroup analyses by publication year

Pooled analysis of 6 study arms published from 2011 onwards showed a significant increased risk for overweight men (pooled RR=1.25, 95% CI: 1.13-1.38), while overweight men in studies published up to 2010 and all overweight women regardless of publication year did not show significant differences with normal weighted individuals (Supplemental Figures 3A, 3B). Similarly, obese males after pooled analysis of 6 study arms published after 2011 showed a significant increased risk (pooled RR=1.29, 95% CI: 1.15-1.44) in contrast with studies published up to 2010. Obese women also showed a significantly increased risk in a pooled analysis

of 11 study arms up to 2010 (pooled RR=1.14, 95% CI: 1.02-1.27), while analysis of 4 studies published after 2011 did not reveal significant difference.

Subgroup analyses, by length of follow-up

Pooled analysis of 8 study arms in overweight men with a median follow-up of <10 years showed a significantly increased risk (pooled RR=1.15, 95% CI: 1.06-1.26), while 9 study arm analysis of overweight men and all analyses of overweight women did not show significant differences. Pooled analysis of 10 study arms for obese males with median follow-up <10 years showed a significantly increased risk (pooled RR=1.18, 95% CI: 1.06-1.31). Similarly, pooled analysis of 6 study arms for obese females with a median follow-up <10 years showed a significantly increased risk (pooled RR=1.34, 95% CI: 1.06-1.71). Analysis of studies with median follow-up \geq 10 years for obese men and women did not reveal significant differences.

Subgroup analyses by sample size

Pooled analysis of 13 study arms regarding overweight men with sample size <300000 showed a significantly increased risk (pooled RR=1.14, 95% CI: 1.04-1.24). Similarly, analysis of 3 study arms for overweight women and sample size \geq 300000 showed a significant increased risk (pooled RR=1.14, 95% CI: 1.01-1.29). Analysis of 13 study arms for obese men and sample size <300000 showed a significantly increased risk (pooled RR=1.19, 95% CI: 1.09-1.31). Analysis of 13 study arms for obese women and sample size <300000 showed a significantly increased risk (pooled RR=1.22, 95% CI: 1.02-1.46).

Subgroup analyses by method of BMI estimation

Pooled analysis of 5 study arms regarding overweight men, where BMI was self-reported showed a significant increased risk (pooled RR=1.14, 95% CI: 1.04-1.25), while analysis of 11 studies where BMI was measured did not reveal significant difference. Pooled analysis of studies regarding overweight women did not reveal any significant differences neither with measured nor with self-reported BMI. Regarding obese males, pooled analysis of 12 studies with measured BMI revealed a significant increased risk (pooled RR=1.11, 95% CI: 1.02-1.20) as well as analysis of 6 studies with self-reported BMI (pooled RR=1.17, 95% CI: 1.04-1.32). Analyses on obese females did not show differences in either subgroups.

Subgroup analyses by adjustment for smoking

Pooled analysis of 16 study arms for overweight men, which adjusted models for smoking habits revealed a significantly increased risk (pooled RR=1.11, 95% CI: 1.03-1.21), while for overweight women no significantly increased risk was found, regardless of adjustment for smoking or not. Pooled analysis of 13 study arms for obese men, which adjusted models for smoking habits, revealed a significantly increased risk (pooled RR=1.13, 95% CI: 1.01-1.27). Analysis of 6 study arms for obese men which did not adjust for smoking, also revealed a significant increased risk (pooled RR=1.14, 95% CI: 1.03-1.27). Analysis of 3 study arms on obese women, which did not adjust for smoking revealed a significantly increased risk (pooled RR=1.14, 95% CI: 1.03-1.27). Analysis of 3 study arms on obese women, which did not adjust for smoking revealed a significantly increased risk (pooled RR=1.27, 95% CI: 1.06-1.52), while analy-

sis of 12 studies that adjusted for smoking did not reveal significant differences.

Height and risk of urinary bladder cancer

Dose-response meta-analysis of 8 studies regarding risk of bladder cancer of every 5 cm increase of height in men revealed no significant association (pooled RR=1.03, 95% CI: 0.99- 1.06, Supplemental Figure 3A). Similarly, a pooled analysis of 5 studies revealed no significant correlation in women per 5 cm increase of height (pooled RR=1.02, 95% CI: 0.97-1.06, Supplemental Figure 3B). Albanes et al [50] and Larsson et al [32] also reported RRs for height and bladder cancer risk without providing



Figure 2. A: Forest plot presenting the association between waist circumference and bladder cancer risk in males. **B:** Forest plot presenting the association between waist circumference and bladder cancer risk in females.

data about incremental estimates; nevertheless, both of these studies found no significant effect of increased height in incidence of bladder cancer in men.

Waist circumference and risk of bladder cancer

Pooled analysis of 3 study arms regarding risk of bladder cancer with increased waist circumference in men, resulted in significant increased risk in a highest vs. lowest (pooled RR=1.18, 95% CI: 1.09-1.26, Figure 2A). On the other hand, pooled analysis of 2 study arms showed no significant risk in women with increased waist circumference (pooled RR=1.13, 95% CI: 0.86-1.48, Figure 2B).

Sensitivity analyses

We performed sensitivity analysis after removing the study by Wolk et al [46] due to potential overlapping population with the study by Larsson et al [32]; the results were similar and remained significant for obese men (pooled RR=1.14, 95% CI: 1.06-1.23). We also performed sensitivity analysis for obese men after removing the study by Leiba et al [41] since it presented overall urothelial cancer, among which 94.4% was located in the bladder; the results also persisted, showing a significantly increased risk (pooled RR=1.12, 95% CI: 1.04-1.21).

Risk of bias and publication bias

Newcastle-Ottawa rating per domain and study are presented in Supplemental Table 1. No evidence of publication bias was detected by visual inspection of funnel plots and after performing Egger's test for outcomes with \geq 10 study arms (Supplemental Table 2).

Discussion

This systematic review and meta-analysis highlight an association between increased bladder cancer risk in overweight and obese men, as well as in obese women. Central obesity also correlated with bladder cancer risk in men, but not women. No associations were noted with height were noted in either sex.

Pooled analysis of twenty prospective cohort studies suggested that an increased risk of bladder cancer by 12% (RR=1.12) in overweight men, while for overweight women the respective difference was not significant. In accordance with our findings, Zhao et al supported that this association becomes significant only at a particular range of BMI, especially for obese people, while for overweight subjects there were no important findings [19]. On the other hand, Sun et al observed a 7% increased

risk in preobese patients [18]. The difference noted between the two sexes is worth commenting. Several studies have proposed the protective role of estrogens in women regarding occurrence of bladder cancer, which is more common in post-menopausal women [52,53]. On the other hand, when considering the same embryologic origin of urinary bladder with prostate and seminal vesicles, such sexspecific differences can be partially explained by the role of androgens on development and growth of bladder tumor cells [54]. At any case, our results indicated that the effect of obesity spanned both sexes, conferring increased risk by 14% in obese men and by 19% in obese women.

After performing subgroup analyses to identify potential sources of heterogeneity, results were similar across several geographical regions except Europe, where different dietary habits among Mediterranean and non- Mediterranean countries could be a source of diversity. Men older than 50 years were those affected the most, probably because of longer duration of increased BMI biological effect, compared to younger patients. Another possible explanation could be the higher incidence of bladder carcinoma at ages \geq 50 y/o. Interestingly, studies where BMI was self-reported showed significant results in contrast to studies with measured BMI. The fact that self-reported anthropometric characteristics can correlate up to a certain degree to realistic measurements according to various crosssectional studies [55] partly ameliorates the implications of this observation in terms of information bias, as overweight and obese individuals tend to underestimate their weight and overestimate their height, which leads to BMI underestimation [56]. In subgroup analyses, studies with a mean followup duration of <10 years showed significant results in contrast with studies with longer follow-up.

Various pathogenic mechanisms that link obesity with bladder cancer have been suggested. A well established link between obesity and insulin resistance along with excess insulin production has been supported; insulin stimulates mitosis and supports carcinogenesis and tumor growth through increased production of insulin-like growth factor I (IGF-I), which further promotes cell proliferation and inhibits programmed cell death [57]. Excess adipose tissue is associated with high levels of cholesterol, which is a prodrome molecule of testosterone [58]. The link between adiposity, mitochondrial dysfunction, increased oxidative stress [59] and leptin secretion, which promotes angiogenesis [60] may also explain this association. Finally, chronic inflammation, as expressed by the increased levels of C-reactive protein and interleukins in the serum of patients with cancer, may also play a role in

the interplay between obesity and bladder cancer [61,62].

Choi et al [39] studied the association between bladder cancer and increased height and found that per 5 cm increased height, risk rose by 8%; however, our systematic review and meta-analysis did not confirm this association. It has been postulated that, similarly with obesity effect, increased organ size translates in more active cell proliferation and potential for DNA mutations [63]. Data from other centers [29,32,33,47-51] support our observation, since no significant difference was detected. Holick et al [33]. interestingly reported an inverse relation and protective role of height regarding urothelial carcinoma; since height depends both on genetic and environmental effects, authors implied that this observation would be explained by poor nutrition during early life, which potentially elevates bladder cancer incidence [33]. Due to conflicting results, further studies are indicated to clarify this aspect.

To the best of our knowledge this is the first meta-analysis studying waist circumference effect on bladder cancer risk. There was an increased risk by 18% for males with increased waist circumference, especially when > 100 cm. The mechanisms proposed pertain to enhanced insulin and IGF-1 action and adipokine pathophysiology [64]. For women, after analysis of 2 arms, no significant difference was noted. Once again, additional studies are needed to investigate this association.

One of the key strengths of this meta-analysis is the inclusion of prospective cohort studies, with large sample sizes and long-term follow-up in most cases. In conjunction with analyzing the largest number of studies, it can provide an accurate estimate of the association between various anthropometric characteristics with bladder cancer

incidence. Heterogeneity was assessed via a large number of subgroup analyses, which showed in general consistent results. The low probability of publication bias is another strength of this systematic review.

Our study however suffers from some limitations. Including studies only in English is a limitation, but since we included the large number of studies when compared to previous reviews, the potential is attenuated. Of course, even though most studies adjusted their model for a number of confounders, the risk of residual confounding is never eliminated, especially in non-randomized studies. Various assessments of obesity and possibility of BMI fluctuation through time is also a matter of concern. Finally, we have chosen not to perform a dose response analysis of BMI and we adhered to the standard classifications of overweight and obese status, to avoid effects of approximation and stay as close to the published data as possible.

In conclusion, our meta-analysis detected an increased risk of bladder cancer in overweight males, obese males and females and males with central obesity. The effect was more pronounced in men older than 50 years, while height did not seem to be a risk factor. Taking into consideration the low number of studies regarding waist circumference, this could be an area of future research.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors

Conflict of interests

The authors declare no conflict of interests.

References

- Abol-Enein H. Infection: is it a cause of bladder cancer? 4. Scand J Urol and Nephrol (Suppl) 2008;218:79-84.
- Ploeg M, Aben KKH, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009;27:289-93.
- Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003;21:1315-30.
- Cooksley CD, Avritscher EB, Grossman HB et al. Clinical model of cost of bladder cancer in the elderly. Urology 2008;71:519-25.
- Schultzel M, Saltzstein SL, Downs TM, Shimasaki S, Sanders C, Sadler GR. Late age (85 years or older) peak incidence of bladder cancer. J Urol 2008;179:1302-5; discussion 5-6.
- Delclos GL, Lerner SP. Occupational risk factors. Scand J Urol Nephrol (Suppl) 2008;218:58-63.

- Reulen RC, Kellen E, Buntinx F, Brinkman M, Zeegers MP. A meta-analysis on the association between bladder cancer and occupation. Scand J Urol Nephrol (Suppl) 2008;218:64-78.
- 8. Harling M, Schablon A, Schedlbauer G, Dulon M, Nienhaus A. Bladder cancer among hairdressers: a metaanalysis. Occupat Environ Med 2010;67:351-8.
- 9. Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 2000;89:630-9.
- Rahman MM, Ng JC, Naidu R. Chronic exposure of arsenic via drinking water and its adverse health impacts on humans. Environm Geochem Health. 2009;31(Suppl 1):189-200.
- 11. Hall P. Radiation-associated urinary bladder cancer. Scand J Urol Nephrol (Suppl) 2008;218:85-8.
- Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006;49:2819-23.
- Brinkman M, Zeegers MP. Nutrition, total fluid and bladder cancer. Scand J Urol Nephrol (Suppl) 2008;218:25-36.
- 14. Ng M, Fleming T, Robinson M et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:766-81.
- 15. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-78.
- Kanabrocki EL, Case LF, Fields T et al. Manganese and copper levels in human urine. Journal of nuclear medicine : official publication, Soc Nuclear Med 1965;6:780-91.
- 17. Qin Q, Xu X, Wang X, Zheng XY. Obesity and risk of bladder cancer: a meta-analysis of cohort studies. Asian Pac J Cancer Prev 2013;14:3117-21.
- Sun JW, Zhao LG, Yang Y, Ma X, Wang YY, Xiang YB. Obesity and risk of bladder cancer: a dose-response meta-analysis of 15 cohort studies. PLoS One. 2015;10:e0119313.
- 19. Zhao L, Tian X, Duan X, Ye Y, Sun M, Huang J. Association of body mass index with bladder cancer risk: a dose-response meta-analysis of prospective cohort studies. Oncotarget 2017;8:33990-4000.
- 20. Psaltopoulou T, Sergentanis TN, Ntanasis-Stathopoulos I et al. Anthropometric characteristics, physical activity and risk of hematological malignancies: A systematic review and meta-analysis of cohort studies. Int J Cancer 2019;145:347-59.
- 21. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62:e1-34.
- 22. Berlin JA, Longnecker MP, Greenland S. Meta-analysis of epidemiologic dose-response data. Epidemiology 1993;4:218-28.
- 23. Higgins JPT GS. Cochrane Handbook for Systematic

Reviews of Interventions Version 5.1.0 [updated March 2011]: The Cochrane Collaboration.; 2011. Available from: www.cochrane-handbook.org.

- 24. GA Wells BS, D O'Connell, J Peterson, V Welch, M Losos, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2016. http://www.ohri.ca/programs/ clinical_epidemiology/oxford.asp
- 25. Jee SH, Yun JE, Park EJ et al. Body mass index and cancer risk in Korean men and women. Int J Cancer 2008;123:1892-6.
- 26. Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 2005;23:4742-54.
- 27. Lee KR, Seo MH, Do Han K, Jung J, Hwang IC. Waist circumference and risk of 23 site-specific cancers: a population-based cohort study of Korean adults. Br J Cancer 2018;119:1018-27.
- 28. Choi JB, Kim JH, Hong SH, Han KD, Ha US. Association of body mass index with bladder cancer risk in men depends on abdominal obesity. World J Urol 2019;37:2393-400.
- 29. Roswall N, Freisling H, Bueno-de-Mesquita HB et al. Anthropometric measures and bladder cancer risk: a prospective study in the EPIC cohort. Int J Cancer 2014;135:2918-29.
- 30. Koebnick C, Michaud D, Moore SC et al. Body mass index, physical activity, and bladder cancer in a large prospective study. Cancer Epidemiol Biomark Prev 2008;17:1214-21.
- Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. Br Med J 2007;335:1134.
- 32. Larsson SC, Andersson SO, Johansson JE, Wolk A. Diabetes mellitus, body size and bladder cancer risk in a prospective study of Swedish men. Eur J Cancer 2008;44:2655-60.
- Holick CN, Giovannucci EL, Stampfer MJ, Michaud DS. Prospective study of body mass index, height, physical activity and incidence of bladder cancer in US men and women. Int J Cancer 2007;120:140-6.
- 34. Cantwell MM, Lacey JV, Jr., Schairer C, Schatzkin A, Michaud DS. Reproductive factors, exogenous hormone use and bladder cancer risk in a prospective study. Int J Cancer 2006;119:2398-401.
- 35. Samanic C, Chow WH, Gridley G, Jarvholm B, Fraumeni JF, Jr. Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control 2006;17:901-9.
- 36. Rapp K, Schroeder J, Klenk J et al. Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br J Cancer 2005;93:1062-7.
- 37. Tripathi A, Folsom AR, Anderson KE. Risk factors for urinary bladder carcinoma in postmenopausal women. The Iowa Women's Health Study. Cancer 2002;95:2316-23.
- Andreotti G, Hou L, Beane Freeman LE et al. Body mass index, agricultural pesticide use, and cancer incidence in the Agricultural Health Study cohort. Cancer Causes Control 2010;21:1759-75.

- 39. Choi YJ, Lee DH, Han KD et al. Adult height in relation to risk of cancer in a cohort of 22,809,722 Korean adults. Br J Cancer 2019;120:668-74.
- 40. Samanic C, Gridley G, Chow WH et al. Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 2004;15:35-43.
- 41. Leiba A, Kark JD, Afek A et al. Overweight in adolescence is related to increased risk of future urothelial cancer. Obesity 2012;20:2445-50.
- 42. Laaksonen MA, MacInnis RJ, Canfell K, Giles GG, Hull P, Shaw JE, et al. The future burden of kidney and bladder cancers preventable by behavior modification in Australia: A pooled cohort study. Int Journal of Cancer 2020;146(3):874-83..
- 43. Kabat GC, Kim MY, Hollenbeck AR, Rohan TE. Attained height, sex, and risk of cancer at different anatomic sites in the NIH-AARP diet and health study. Cancer Causes Control 2014;25:1697-706.
- 44. Haggstrom C, Stocks T, Rapp K et al. Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project. Int J Cancer 2011;128:1890-8.
- 45. Song X, Pukkala E, Dyba T et al. Body mass index and cancer incidence: the FINRISK study. Eur J Epidemiol 2014;29:477-87.
- 46. Wolk A, Gridley G, Svensson M et al. A prospective study of obesity and cancer risk. Cancer Causes Control 2001;12:13-21.
- 47. Kabat GC, Heo M, Kamensky V, Miller AB, Rohan TE. Adult height in relation to risk of cancer in a cohort of Canadian women. Int J Cancer 2013;132:1125-32.
- 48. Kabat GC, Anderson ML, Heo M et al. Adult stature and risk of cancer at different anatomic sites in a cohort of postmenopausal women. Cancer Epidemiol Biomark Prev 2013;22:1353-63.
- 49. Green J, Cairns BJ, Casabonne D et al. Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol 2011;12:785-94.
- 50. Albanes D, Jones DY, Schatzkin A, Micozzi MS, Taylor PR. Adult Stature and Risk of Cancer. Cancer Res 1988;48:1658-62.
- 51. Wiren S, Haggstrom C, Ulmer H et al. Pooled cohort study on height and risk of cancer and cancer death. Cancer Causes Control 2014;25:151-9.

- 52. McGrath M, Michaud DS, De Vivo I. Hormonal and reproductive factors and the risk of bladder cancer in women. Am J Epidemiol 2006;163:236-44.
- 53. Scosyrev E, Noyes K, Feng C, Messing E. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 2009;115:68-74.
- 54. Rosenzweig BA, Bolina PS, Birch L et al. Location and concentration of estrogen, progesterone, and androgen receptors in the bladder and urethra of the rabbit. Neurourol Urodynam 1995;14:87-96.
- 55. Spencer EA, Roddam AW, Key TJ. Accuracy of selfreported waist and hip measurements in 4492 EPIC-Oxford participants. Public Health Nutr 2004;7:723-7.
- 56. Connor Gorber S, Tremblay M, Moher D, Gorber B. A comparison of direct vs. self-report measures for assessing height, weight and body mass index: a systematic review. Obesity Rev 2007;8:307-26.
- 57. Zhao H, Grossman HB, Spitz MRNet al. Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol 2003;169:714-7.
- 58. Montella M, Di Maso M, Crispo A et al. Metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study. BMC Cancer 2015;15: 720.
- 59. Beckman KB, Ames BN. Oxidative decay of DNA. J Biol Chem 1997;272:19633-6.
- 60. Cirillo D, Rachiglio AM, la Montagna R et al. Leptin signaling in breast cancer: an overview. J Cell Biochem 2008;105:956-64.
- 61. Hilmy M, Bartlett JM, Underwood MA, McMillan DC. The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 2005;92:625-7.
- 62. Andrews B, Shariat SF, Kim JH et al. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol 2002;167:1475-81.
- 63. Albanes D, Winick M. Are cell number and cell proliferation risk factors for cancer? J Natl Cancer Inst 1988;80:772-4.
- 64. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nature Rev Cancer 2011;11:886-95.

Representationes Soluction details Componential for the sector of a componential detail det	Study ID		Selection	ion			Comparability			Outcome
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		Representativeness		Ascertainment of exposure	Outcome not present at start	Comparability on age	Comparability on other risk factors	Assessment of outcome	Long enough follow-up (median ≥10 years)	Adequacy (completeness) of follow-up (≥85% response rate)
019) 0 050 0 01 0 01 0 01 0 01 0 01 0 01 0 01 0 01 0 01 0 01 0 01 0 010 0 011 0 012 0 013 0 014 0 015 0 016 0 017 0 018 0 019 0 019 0 019 0 019 0 020 0 031 0 04 0 05 0 06 0 07 0 08 0 09 0 010 0 011 0 021 0	Albanes (1988)		*	*	*	*	*	*	*	
06) • • • • • • • 0) • • • • • • • 0) • • • • • • • 0) • • • • • • • 0) • • • • • • • 2010) • • • • • • • 0 • • • • • • • 008 • • • • • • • 010 • • • • • • • 02010 • • • • • • • 038 • • • • • • • 0301 • • • • • • • 031 • • • • • • • 031 • • • • • • • 031 • • • • • • • <td>Andreotti (2019)</td> <td>*</td> <td>*</td> <td>·</td> <td>*</td> <td>*</td> <td>*</td> <td>ı</td> <td>·</td> <td>*</td>	Andreotti (2019)	*	*	·	*	*	*	ı	·	*
9) •• <td< td=""><td>Cantwell (2006)</td><td>*</td><td>*</td><td>×</td><td>*</td><td>*</td><td>*</td><td>*</td><td>ı</td><td>*</td></td<>	Cantwell (2006)	*	*	×	*	*	*	*	ı	*
	Choi JB (2019)	*	*	×	*	*	*	*	·	*
	Choi YJ (2019)	*	*	×	×	*	*		,	
	Green (2011)	*	*	ı	×	*	*	*	ı	*
	Haggstrom (2010)	*	*	*	*	*	*	*	*	*
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Holick (2007)	*	*	ı	*	*	*	*	*	*
	Jee (2008)	*	*	×	*	*	*	*	*	*
	Kabat (2012)	*	*	×	×	*		*	*	*
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Kabat (2013)	*	*	×	×	*	*	·	*	
03) *	Kabat (2014)	*	*	·	×	*	*	*	*	*
2019) * <td>Koebnick (2008)</td> <td>*</td> <td>*</td> <td></td> <td>*</td> <td>*</td> <td></td> <td>*</td> <td>ı</td> <td>*</td>	Koebnick (2008)	*	*		*	*		*	ı	*
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Laaksonen (2019)	*	×	ı	×	*	*	*	,	*
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Larsson (2007)	ı	*	ı	*	*	*	*	,	*
(1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	Leiba (2012)	ı	*	*	×	*		*	*	*
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Oh (2005)	*	*	*	÷	*	*	*	ı	*
	Rapp (2005)	*	*	×	*	*	*	*	- (males) * (females)	*
 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 	Reeves (2007)	*	*		*	*	*	*	ı	*
* * * * * * * *	Roswall (2014)	*	*	*	*	*	*	*	*	*
	Samanic (2006)	*	*	×	ı	*	*	*	*	*
	Samanic (2004)	*	*	*	*	*		*	×	*
	Song (2014)	*	*	*	*	*	*	*	×	*
2) * * * * * * * * * * * * * * * * * * *	Teleka (2018)	*	*	*	*	*	*	*	*	*
* * * * * *	Tripathi (2002)	*	*	I	*	*	*	*	ı	*
* * * *	Wiren (2013)	*	*	×	*	*	ı	*	*	*
	Wolk (2001)	*	*	¥	*	*	ı	*	- (males) * (females)	*

Supplemental Table 2. Publication bias assessment by Egger's test

Outcome	Egger's test p value
Men overweight	0.557
Men obese	0.917
Women overweight	0.864
Women obese	0.708



Supplemental Figure 1. Flow diagram for study selection. *The male arm in the study by Jee (2008) et al. was excluded due to overlap with the study by Oh et al. that spanned a longer time period (1992-2001 *vs.* 1992-1995) *The male arm in the study by Lee et al (2018) was excluded due to overlap with the study by Choi J.B. et al that spanned the same time period (2009-2015).

Α

Study		%
D	RR (95% CI)	Weight
Mean age <50 y		
Andreotti males BMI 25.0-29.9 (2010)	 1.16 (0.75, 1.80)	2.27
Choi JB males BMI 25.0-29.9 (2019)	1.19 (1.15, 1.23)	12.33
Haggstrom males BMI 25.4 (2010)	 1.06 (0.89, 1.27)	7.20
Happstrom males BMI 27.1 (2010)	 0.97 (0.81, 1.17)	6.98

Haggstrom males BMI 25.4 (2010)	1.06 (0.89, 1.2	7) 7.20
Haggstrom males BMI 27.1 (2010)	0.97 (0.81, 1.1	7) 6.98
Oh males BMI 25.0-26.9 (2005)	1.12 (0.89, 1.4	1) 5.64
Oh males BMI 27.0-29.9 (2005)	1.16 (0.83, 1.6	2) 3.53
Rapp males BMI 25.0-29.9 (2005)	0.81 (0.59, 1.1	1) 3.78
Samanic males BMI 25.0-29.9 (2006)	0.94 (0.86, 1.0	3) 10.62
Song males BMI 25.0-27.4 (2014)	1.48 (0.95, 2.3	1) 2.22
Song males BMI 27.5-29.9 (2014)	1.95(1.24, 3.0	8) 2.14
Subtotal (I-squared = 76.5%, p = 0.000)	1.09 (0.97, 1.2	3) 56.72
Mean age >=50 y		
Holick males BM 25.0-26.9 (2007)	1.14 (0.86, 1.5	1) 4.42
Holick males BMI 27.0-29.9 (2007)	1.12 (0.83, 1.5	1) 4.07
Koebnick males BMI 25.0-29.9 (2008)	1.21 (1.07, 1.3	7) 9.31
Laaksonen males BMI 25.0-29.9 (2019)	1.51 (1.15, 1.9	8) 4.62
Larsson males BMI 25.0-29.9 (2007)	0.98 (0.80, 1.2	1) 6.24
Roswall males BMI 24.52-26.45 (2014)	1.20 (1.01, 1.4	3) 7.40
Roswall males BMI 26.46-28.96 (2014)	1.11 (0.93, 1.3	3) 7.22
Subtotal ()-squared = 13.8%, p = 0.324)	1.17 (1.08, 1.2)	7) 43.28
Overall (i-squared = 64.8%, p = 0.000)	1.12(1.04, 1.2	1) 100.00
NOTE: Weights are from random effects analysis		
.325	1 3.08	



Supplemental Figure 2. A: Forest plot of subgroup analysis, by age in overweight males. B: Forest plot of subgroup analysis, by age in overweight females.

Study ID	RR (95% Cl)	% Weigh
Mean age <50 y		
Andreotti males BMI 30.0-34.9 (2010)	1.41 (0.82, 2.42)	1.60
Choi JB males BMI >=30.0 (2019)	→ 1.17 (1.06, 1.30)	13.15
Haggstrom males BMI 30.8 (2010)	+ 1.13 (0.94, 1.35)	8.35
Leiba males BMI >=25.0 (2012)	1.36 (1.08, 1.72)	6.19
Oh males BMI >=30.0 (2005)	0.70 (0.22, 2.21)	0.38
Rapp males BMI >=30.0 (2005)	0.74 (0.45, 1.22)	1.85
Samanic black males BMI >= 30.0 (2004)	0.85 (0.67, 1.08)	5.99
Samanic males BMI >30.0 (2006)	• 0.91 (0.76, 1.09)	8.39
Song males BMI 30-34.9 (2014)	1.47 (0.85, 2.53)	1.58
Song males BMI >=35.0 (2014)	• 1.91 (0.74, 4.95)	0.55
Wolk males BMI >30 (2001)	1.10 (0.78, 1.56)	3.44
Subtotal (I-squared = 49.0%, p = 0.033)	1.09 (0.96, 1.23)	51.47
Mean age >=50 y		
Holick males BMI >=30 (2007)	1.01 (0.68, 1.50)	2.77
Koebnick males BMI 30.0-34.9 (2008)	+ 1.21 (1.03, 1.43)	9.23
Koebnick males BMI >=35.0 (2008)	1.25 (0.96, 1.63)	5.19
Laaksonen males BMI >=30.0 (2019)	1.70 (1.23, 2.34)	3.88
Larsson males BMI 30.0-34.9 (2007)	0.92 (0.63, 1.35)	2.89
Larsson males BMI >=35 (2007)	0.79 (0.29, 2.15)	0.50
Roswall males BMI >=28.97 (2014)	1.25 (1.04, 1.50)	8.25
Samanic white males BMI >=30.0 (2004)	➡ 1.13 (1.06, 1.20)	15.83
Subtotal (I-squared = 28.0%, p = 0.204)	1.18 (1.08, 1.29)	48.53
Overall (I-squared = 40.9%, p = 0.033)	1.14 (1.06, 1.22)	100.0
NOTE: Weights are from random effects analysis		
.202	1 4.95	



Supplemental Figure 2. C: Forest plot of subgroup analysis, by age in obese males. **D:** Forest plot of subgroup analysis, by age in obese females

Study ID	RR (95% Cl)	% We
East Asia		
Choi YJ males height per 5 cm increase (2019)	1.08 (1.07, 1.10) 24.
Subtotal (I-squared = .%, p = .)	1.08 (1.07, 1.10) 24.
Europe		
Roswall males height per 5 cm increase (2014)	0.96 (0.91, 1.02) 17.
Wiren males height per 5 cm increase (2013)	1.03 (0.99, 1.07) 20.
Subtotal (I-squared = 75.0%, p = 0.046)	1.00 (0.93, 1.07) 37.
US/Canada		
Holick males height per 5 cm increase (2007)	0.94 (0.88, 1.00) 15
Kabat males height per 5 cm increase (2014)	1.03 (1.01, 1.06) 22.
Subtotal (I-squared = 86.2%, p = 0.007)	0.99 (0.90, 1.09	
Overall (I-squared = 89.2%, p = 0.000)	1.02 (0.97, 1.06) 10
NOTE: Weights are from random effects analysis		
.877 1	1.14	%
Study	1.14 RR (95% CI)	% W
Study ID		
Study ID East Asia	RR (95% CI)	w
Study ID East Asia Choi YJ females height per 5 cm incease (2019)	RR (95% Cl)	W) 24
Study ID East Asia	RR (95% CI)	W) 24
Study ID East Asia Choi YJ females height per 5 cm incease (2019)	RR (95% Cl)	W) 24
Study ID East Asia Choi YJ females height per 5 cm incease (2019) Subtotal (I-squared = .%, p = .)	RR (95% Cl)	W) 24) 24
Study ID East Asia Choi YJ females height per 5 cm incease (2019) Subtotal (I-squared = .%, p = .) Europe	RR (95% Cl) 1.08 (1.05, 1.11 1.08 (1.05, 1.11	W) 24) 24) 14
Study ID East Asia Choi YJ females height per 5 cm incease (2019) Subtotal (I-squared = .%, p = .) Europe Green females height per 5 cm increase (2011)	RR (95% Cl) 1.08 (1.05, 1.11 1.08 (1.05, 1.11 1.08 (1.05, 1.11 1.00 (0.94, 1.07 1.06 (0.97, 1.16	W) 24) 24) 14) 9.4
Study ID East Asia Choi YJ females height per 5 cm incease (2019) Subtotal (I-squared = .%, p = .) Europe Green females height per 5 cm increase (2011) Roswall females height per 5 cm increase (2014)	RR (95% Cl) 1.08 (1.05, 1.11 1.08 (1.05, 1.11 1.08 (1.05, 1.11 1.00 (0.94, 1.07 1.06 (0.97, 1.16	W) 24) 24) 14) 9.1
Study ID East Asia Choi YJ females height per 5 cm incease (2019) Subtotal (I-squared = .%, p = .) Europe Green females height per 5 cm increase (2011) Roswall females height per 5 cm increase (2014) Wiren females height per 5 cm increase (2013)	RR (95% Cl) 1.08 (1.05, 1.11 1.08 (1.05, 1.11 1.08 (1.05, 1.11 1.00 (0.94, 1.07 1.06 (0.97, 1.16 1.01 (0.92, 1.10	W) 24) 24) 14) 9.4
Study ID East Asia Choi YJ females height per 5 cm incease (2019) Subtotal (I-squared = .%, p = .) Europe Green females height per 5 cm increase (2011) Roswall females height per 5 cm increase (2014) Wiren females height per 5 cm increase (2013) Subtotal (I-squared = 0.0%, p = 0.575)	RR (95% Cl) 1.08 (1.05, 1.11 1.08 (1.05, 1.11 1.08 (1.05, 1.11 1.00 (0.94, 1.07 1.06 (0.97, 1.16 1.01 (0.92, 1.10	W) 24) 24) 9.4) 9.6) 33
Study ID East Asia Choi YJ females height per 5 cm incease (2019) Subtotal (I-squared = .%, p = .) Europe Green females height per 5 cm increase (2011) Roswall females height per 5 cm increase (2014) Wiren females height per 5 cm increase (2013) Subtotal (I-squared = 0.0%, p = 0.575) US/Canada	RR (95% Cl) 1.08 (1.05, 1.11 1.08 (1.05, 1.11 1.01 (0.92, 1.10 1.02 (0.97, 1.06 0.98 (0.90, 1.07 1.02 (0.90, 1.17 1.02 (0.90, 1.17) 1.02 (0.90, 1.17)	W) 24) 24) 9.4) 9.4) 9.5) 33
Study ID East Asia Choi YJ females height per 5 cm incease (2019) Subtotal (I-squared = .%, p = .) Europe Green females height per 5 cm increase (2011) Roswall females height per 5 cm increase (2014) Wiren females height per 5 cm increase (2013) Subtotal (I-squared = 0.0%, p = 0.575) US/Canada Holick females height per 5 cm increase (2007)	RR (95% Cl)	W) 24) 24) 9.4) 9.4) 9.6) 33
Study ID East Asia Choi YJ females height per 5 cm incease (2019) Subtotal (I-squared = .%, p = .) Europe Green females height per 5 cm increase (2011) Roswall females height per 5 cm increase (2014) Wiren females height per 5 cm increase (2013) Subtotal (I-squared = 0.0%, p = 0.575) US/Canada Holick females height per 5 cm increase (2007) Kabat females height per 5 cm increase (2012)	RR (95% Cl) 1.08 (1.05, 1.11 1.08 (1.05, 1.11 1.06 (0.97, 1.16 1.01 (0.92, 1.10 1.02 (0.97, 1.06 0.98 (0.90, 1.07 1.02 (0.90, 1.17) 1.02 (0.90, 1.17)	W) 24) 24) 9.4) 9.4) 9.3 3 3) 9.1) 5.4
Study ID East Asia Choi YJ females height per 5 cm incease (2019) Subtotal (I-squared = .%, p = .) Europe Green females height per 5 cm increase (2011) Roswall females height per 5 cm increase (2014) Wiren females height per 5 cm increase (2013) Subtotal (I-squared = 0.0%, p = 0.575) US/Canada Holick females height per 5 cm increase (2007) Kabat females height per 5 cm increase (2012) Kabat females height per 5 cm increase (2013)	RR (95% Cl) 1.08 (1.05, 1.11 1.08 (1.05, 1.11 1.08 (1.05, 1.11 1.08 (1.05, 1.11 1.08 (1.05, 1.11 1.08 (1.05, 1.11 1.08 (1.05, 1.11 1.02 (0.97, 1.16 0.98 (0.90, 1.07 1.02 (0.90, 1.17 1.02 (0.95, 1.11	W) 24) 24) 24) 9.4) 9.1) 9.0) 9.1) 5.4
Study ID East Asia Choi YJ females height per 5 cm incease (2019) Subtotal (I-squared = .%, p = .) Europe Green females height per 5 cm increase (2011) Roswall females height per 5 cm increase (2014) Wiren females height per 5 cm increase (2013) Subtotal (I-squared = 0.0%, p = 0.575) US/Canada Holick females height per 5 cm increase (2007) Kabat females height per 5 cm increase (2012) Kabat females height per 5 cm increase (2013) Kabat females height per 5 cm increase (2013) Kabat females height per 5 cm increase (2014)	RR (95% Cl) 1.08 (1.05, 1.11 1.08 (1.05, 1.11 1.08 (1.05, 1.11 1.00 (0.94, 1.07 1.06 (0.97, 1.16 1.01 (0.92, 1.10 1.02 (0.97, 1.06 0.98 (0.90, 1.07 1.02 (0.95, 1.11 0.99 (0.93, 1.05 0.99 (0.93, 1.05 0.90 (0.91, 1.05 0.90 (0.91, 1.05 0.90 (0.93, 1.05 0.90 (0.91, 1.05	W) 24) 24) 24) 9.4) 9.1) 9.0) 9.1) 5.4
Study ID East Asia Choi YJ females height per 5 cm incease (2019) Subtotal (I-squared = .%, p = .) Europe Green females height per 5 cm increase (2011) Roswall females height per 5 cm increase (2014) Wiren females height per 5 cm increase (2013) Subtotal (I-squared = 0.0%, p = 0.575) US/Canada Holick females height per 5 cm increase (2007) Kabat females height per 5 cm increase (2012) Kabat females height per 5 cm increase (2013) Kabat females height per 5 cm increase (2013) Kabat females height per 5 cm increase (2014)	RR (95% Cl) 1.08 (1.05, 1.11 1.08 (1.05, 1.11 1.08 (1.05, 1.11 1.00 (0.94, 1.07 1.06 (0.97, 1.16 1.01 (0.92, 1.10 1.02 (0.97, 1.06 0.98 (0.90, 1.07 1.02 (0.95, 1.11 0.99 (0.93, 1.05 0.99 (0.93, 1.05 0.90 (0.91, 1.05 0.90 (0.91, 1.05 0.90 (0.93, 1.05 0.90 (0.91, 1.05	W.) 24) 24) 14) 9.4) 9.7) 5.4) 11) 15) 41

Supplemental Figure 3. A: Forest plot for height increase per 5 cm in males. **B:** Forest plot for height increase per 5 cm in females.